Data source Date of update Product name Alternative name Product type Non-traditionals categories Antibacterial class Indications Route of administration R&D phase Clinical trials Developer Pathogen category Pathogen name Pathogen activity Active against priority pathogens? Innovative? NCE? Mycobacterium tuberculosis Clostridioides difficile WHO AMR pipeline analysis Nov-21 "Bacteriophage" Non-traditional Bacteriophages and phage-derived enzymes Bacteriophage Gram positive and Gram negative Inhalation Phase III NCT04682964 "Tashkent Pediatric Medical Institute" Priority pathogens Streptococcus pneumoniae Other priority pathogens Yes N/A Yes NA NA WHO AMR pipeline analysis Nov-21 "Bacteriophage" Non-traditional Bacteriophages and phage-derived enzymes Bacteriophage Gram positive and Gram negative Inhalation Phase III NCT04682964 "Tashkent Pediatric Medical Institute" Priority pathogens Staphylococcus aureus Other priority pathogens Yes N/A Yes NA NA WHO AMR pipeline analysis Nov-21 "Bacteriophage" Non-traditional Bacteriophages and phage-derived enzymes Bacteriophage Gram positive and Gram negative Inhalation Phase III NCT04682964 "Tashkent Pediatric Medical Institute" Priority pathogens Pseudomonas aeruginosa Critical priority pathogens Yes N/A Yes NA NA WHO AMR pipeline analysis Nov-21 "Bacteriophage" Non-traditional Bacteriophages and phage-derived enzymes Bacteriophage Gram positive and Gram negative Inhalation Phase III NCT04682964 "Tashkent Pediatric Medical Institute" Priority pathogens Other priority pathogens Other priority pathogens Yes N/A Yes NA NA WHO AMR pipeline analysis Nov-21 "Bacteriophage" Non-traditional Bacteriophages and phage-derived enzymes Bacteriophage Gram positive and Gram negative Inhalation Phase III NCT04682964 "Tashkent Pediatric Medical Institute" Priority pathogens Neisseria gonnorhoeae Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 "Bacteriophage" Non-traditional Bacteriophages and phage-derived enzymes Bacteriophage Gram positive and Gram negative Inhalation Phase III NCT04682964 "Tashkent Pediatric Medical Institute" Priority pathogens Helicobacter pylori Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 "Bacteriophage" Non-traditional Bacteriophages and phage-derived enzymes Bacteriophage Gram positive and Gram negative Inhalation Phase III NCT04682964 "Tashkent Pediatric Medical Institute" Priority pathogens Gram-positive priority pathogens Other priority pathogens Yes N/A Yes NA NA WHO AMR pipeline analysis Nov-21 "Bacteriophage" Non-traditional Bacteriophages and phage-derived enzymes Bacteriophage Gram positive and Gram negative Inhalation Phase III NCT04682964 "Tashkent Pediatric Medical Institute" Priority pathogens Enterococcus faecium Other priority pathogens Yes N/A Yes NA NA WHO AMR pipeline analysis Nov-21 "Bacteriophage" Non-traditional Bacteriophages and phage-derived enzymes Bacteriophage Gram positive and Gram negative Inhalation Phase III NCT04682964 "Tashkent Pediatric Medical Institute" Priority pathogens Enterobacterales Critical priority pathogens Yes N/A Yes NA NA WHO AMR pipeline analysis Nov-21 "Bacteriophage" Non-traditional Bacteriophages and phage-derived enzymes Bacteriophage Gram positive and Gram negative Inhalation Phase III NCT04682964 "Tashkent Pediatric Medical Institute" Priority pathogens Critical priority pathogens Critical priority pathogens Yes N/A Yes NA NA WHO AMR pipeline analysis Nov-21 "Bacteriophage" Non-traditional Bacteriophages and phage-derived enzymes Bacteriophage Gram positive and Gram negative Inhalation Phase III NCT04682964 "Tashkent Pediatric Medical Institute" Priority pathogens Campylobacter spp. Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 "Bacteriophage" Non-traditional Bacteriophages and phage-derived enzymes Bacteriophage Gram positive and Gram negative Inhalation Phase III NCT04682964 "Tashkent Pediatric Medical Institute" Priority pathogens All critical priority pathogens Critical priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 "Bacteriophage" Non-traditional Bacteriophages and phage-derived enzymes Bacteriophage Gram positive and Gram negative Inhalation Phase III NCT04682964 "Tashkent Pediatric Medical Institute" Priority pathogens Acinetobacter baumannii Critical priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 9MW1411 - Non-traditional Antibodies Monoclonal antibody S. aureus IV Phase I NCT04784312 Mabwell Bioscience Priority pathogens Streptococcus pneumoniae Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 9MW1411 - Non-traditional Antibodies Monoclonal antibody S. aureus IV Phase I NCT04784312 Mabwell Bioscience Priority pathogens Staphylococcus aureus Other priority pathogens Yes N/A Yes NA NA WHO AMR pipeline analysis Nov-21 9MW1411 - Non-traditional Antibodies Monoclonal antibody S. aureus IV Phase I NCT04784312 Mabwell Bioscience Priority pathogens Pseudomonas aeruginosa Critical priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 9MW1411 - Non-traditional Antibodies Monoclonal antibody S. aureus IV Phase I NCT04784312 Mabwell Bioscience Priority pathogens Other priority pathogens Other priority pathogens Yes N/A Yes NA NA WHO AMR pipeline analysis Nov-21 9MW1411 - Non-traditional Antibodies Monoclonal antibody S. aureus IV Phase I NCT04784312 Mabwell Bioscience Priority pathogens Neisseria gonnorhoeae Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 9MW1411 - Non-traditional Antibodies Monoclonal antibody S. aureus IV Phase I NCT04784312 Mabwell Bioscience Priority pathogens Helicobacter pylori Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 9MW1411 - Non-traditional Antibodies Monoclonal antibody S. aureus IV Phase I NCT04784312 Mabwell Bioscience Priority pathogens Gram-positive priority pathogens Other priority pathogens Yes N/A Yes NA NA WHO AMR pipeline analysis Nov-21 9MW1411 - Non-traditional Antibodies Monoclonal antibody S. aureus IV Phase I NCT04784312 Mabwell Bioscience Priority pathogens Enterococcus faecium Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 9MW1411 - Non-traditional Antibodies Monoclonal antibody S. aureus IV Phase I NCT04784312 Mabwell Bioscience Priority pathogens Enterobacterales Critical priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 9MW1411 - Non-traditional Antibodies Monoclonal antibody S. aureus IV Phase I NCT04784312 Mabwell Bioscience Priority pathogens Critical priority pathogens Critical priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 9MW1411 - Non-traditional Antibodies Monoclonal antibody S. aureus IV Phase I NCT04784312 Mabwell Bioscience Priority pathogens Campylobacter spp. Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 9MW1411 - Non-traditional Antibodies Monoclonal antibody S. aureus IV Phase I NCT04784312 Mabwell Bioscience Priority pathogens All critical priority pathogens Critical priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 9MW1411 - Non-traditional Antibodies Monoclonal antibody S. aureus IV Phase I NCT04784312 Mabwell Bioscience Priority pathogens Acinetobacter baumannii Critical priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 AB103 Reltecimod Non-traditional Immunomodulating agents Antagonist of superantigen exotoxins and CD28 T-cell S. aureus necrotizing soft tissue infection, acute kidney injury, peritonitis IV Preregistration NCT02469857, NCT03403751 Atox Bio Priority pathogens Streptococcus pneumoniae Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 AB103 Reltecimod Non-traditional Immunomodulating agents Antagonist of superantigen exotoxins and CD28 T-cell S. aureus necrotizing soft tissue infection, acute kidney injury, peritonitis IV Preregistration NCT02469857, NCT03403751 Atox Bio Priority pathogens Staphylococcus aureus Other priority pathogens Yes N/A Yes NA NA WHO AMR pipeline analysis Nov-21 AB103 Reltecimod Non-traditional Immunomodulating agents Antagonist of superantigen exotoxins and CD28 T-cell S. aureus necrotizing soft tissue infection, acute kidney injury, peritonitis IV Preregistration NCT02469857, NCT03403751 Atox Bio Priority pathogens Pseudomonas aeruginosa Critical priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 AB103 Reltecimod Non-traditional Immunomodulating agents Antagonist of superantigen exotoxins and CD28 T-cell S. aureus necrotizing soft tissue infection, acute kidney injury, peritonitis IV Preregistration NCT02469857, NCT03403751 Atox Bio Priority pathogens Other priority pathogens Other priority pathogens Yes N/A Yes NA NA WHO AMR pipeline analysis Nov-21 AB103 Reltecimod Non-traditional Immunomodulating agents Antagonist of superantigen exotoxins and CD28 T-cell S. aureus necrotizing soft tissue infection, acute kidney injury, peritonitis IV Preregistration NCT02469857, NCT03403751 Atox Bio Priority pathogens Neisseria gonnorhoeae Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 AB103 Reltecimod Non-traditional Immunomodulating agents Antagonist of superantigen exotoxins and CD28 T-cell S. aureus necrotizing soft tissue infection, acute kidney injury, peritonitis IV Preregistration NCT02469857, NCT03403751 Atox Bio Priority pathogens Helicobacter pylori Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 AB103 Reltecimod Non-traditional Immunomodulating agents Antagonist of superantigen exotoxins and CD28 T-cell S. aureus necrotizing soft tissue infection, acute kidney injury, peritonitis IV Preregistration NCT02469857, NCT03403751 Atox Bio Priority pathogens Gram-positive priority pathogens Other priority pathogens Yes N/A Yes NA NA WHO AMR pipeline analysis Nov-21 AB103 Reltecimod Non-traditional Immunomodulating agents Antagonist of superantigen exotoxins and CD28 T-cell S. aureus necrotizing soft tissue infection, acute kidney injury, peritonitis IV Preregistration NCT02469857, NCT03403751 Atox Bio Priority pathogens Enterococcus faecium Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 AB103 Reltecimod Non-traditional Immunomodulating agents Antagonist of superantigen exotoxins and CD28 T-cell S. aureus necrotizing soft tissue infection, acute kidney injury, peritonitis IV Preregistration NCT02469857, NCT03403751 Atox Bio Priority pathogens Enterobacterales Critical priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 AB103 Reltecimod Non-traditional Immunomodulating agents Antagonist of superantigen exotoxins and CD28 T-cell S. aureus necrotizing soft tissue infection, acute kidney injury, peritonitis IV Preregistration NCT02469857, NCT03403751 Atox Bio Priority pathogens Critical priority pathogens Critical priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 AB103 Reltecimod Non-traditional Immunomodulating agents Antagonist of superantigen exotoxins and CD28 T-cell S. aureus necrotizing soft tissue infection, acute kidney injury, peritonitis IV Preregistration NCT02469857, NCT03403751 Atox Bio Priority pathogens Campylobacter spp. Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 AB103 Reltecimod Non-traditional Immunomodulating agents Antagonist of superantigen exotoxins and CD28 T-cell S. aureus necrotizing soft tissue infection, acute kidney injury, peritonitis IV Preregistration NCT02469857, NCT03403751 Atox Bio Priority pathogens All critical priority pathogens Critical priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 AB103 Reltecimod Non-traditional Immunomodulating agents Antagonist of superantigen exotoxins and CD28 T-cell S. aureus necrotizing soft tissue infection, acute kidney injury, peritonitis IV Preregistration NCT02469857, NCT03403751 Atox Bio Priority pathogens Acinetobacter baumannii Critical priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 Afabicin Debio 1450 Antibiotics NA FabI inhibitor ABSSI (caused by S. aureus), osteomyelitis IV, Oral Phase II NCT02426918, NCT03723551 Debiopharm International SA Priority pathogens Streptococcus pneumoniae Other priority pathogens No Yes Yes NA NA WHO AMR pipeline analysis Nov-21 Afabicin Debio 1450 Antibiotics NA FabI inhibitor ABSSI (caused by S. aureus), osteomyelitis IV, Oral Phase II NCT02426918, NCT03723551 Debiopharm International SA Priority pathogens Staphylococcus aureus Other priority pathogens Yes Yes Yes NA NA WHO AMR pipeline analysis Nov-21 Afabicin Debio 1450 Antibiotics NA FabI inhibitor ABSSI (caused by S. aureus), osteomyelitis IV, Oral Phase II NCT02426918, NCT03723551 Debiopharm International SA Priority pathogens Pseudomonas aeruginosa Critical priority pathogens No Yes Yes NA NA WHO AMR pipeline analysis Nov-21 Afabicin Debio 1450 Antibiotics NA FabI inhibitor ABSSI (caused by S. aureus), osteomyelitis IV, Oral Phase II NCT02426918, NCT03723551 Debiopharm International SA Priority pathogens Other priority pathogens Other priority pathogens Yes Yes Yes NA NA WHO AMR pipeline analysis Nov-21 Afabicin Debio 1450 Antibiotics NA FabI inhibitor ABSSI (caused by S. aureus), osteomyelitis IV, Oral Phase II NCT02426918, NCT03723551 Debiopharm International SA Priority pathogens Neisseria gonnorhoeae Other priority pathogens No Yes Yes NA NA WHO AMR pipeline analysis Nov-21 Afabicin Debio 1450 Antibiotics NA FabI inhibitor ABSSI (caused by S. aureus), osteomyelitis IV, Oral Phase II NCT02426918, NCT03723551 Debiopharm International SA Priority pathogens Helicobacter pylori Other priority pathogens No Yes Yes NA NA WHO AMR pipeline analysis Nov-21 Afabicin Debio 1450 Antibiotics NA FabI inhibitor ABSSI (caused by S. aureus), osteomyelitis IV, Oral Phase II NCT02426918, NCT03723551 Debiopharm International SA Priority pathogens Gram-positive priority pathogens Other priority pathogens Yes Yes Yes NA NA WHO AMR pipeline analysis Nov-21 Afabicin Debio 1450 Antibiotics NA FabI inhibitor ABSSI (caused by S. aureus), osteomyelitis IV, Oral Phase II NCT02426918, NCT03723551 Debiopharm International SA Priority pathogens Enterococcus faecium Other priority pathogens No Yes Yes NA NA WHO AMR pipeline analysis Nov-21 Afabicin Debio 1450 Antibiotics NA FabI inhibitor ABSSI (caused by S. aureus), osteomyelitis IV, Oral Phase II NCT02426918, NCT03723551 Debiopharm International SA Priority pathogens Enterobacterales Critical priority pathogens No Yes Yes NA NA WHO AMR pipeline analysis Nov-21 Afabicin Debio 1450 Antibiotics NA FabI inhibitor ABSSI (caused by S. aureus), osteomyelitis IV, Oral Phase II NCT02426918, NCT03723551 Debiopharm International SA Priority pathogens Critical priority pathogens Critical priority pathogens No Yes Yes NA NA WHO AMR pipeline analysis Nov-21 Afabicin Debio 1450 Antibiotics NA FabI inhibitor ABSSI (caused by S. aureus), osteomyelitis IV, Oral Phase II NCT02426918, NCT03723551 Debiopharm International SA Priority pathogens Campylobacter spp. Other priority pathogens No Yes Yes NA NA WHO AMR pipeline analysis Nov-21 Afabicin Debio 1450 Antibiotics NA FabI inhibitor ABSSI (caused by S. aureus), osteomyelitis IV, Oral Phase II NCT02426918, NCT03723551 Debiopharm International SA Priority pathogens All critical priority pathogens Critical priority pathogens No Yes Yes NA NA WHO AMR pipeline analysis Nov-21 Afabicin Debio 1450 Antibiotics NA FabI inhibitor ABSSI (caused by S. aureus), osteomyelitis IV, Oral Phase II NCT02426918, NCT03723551 Debiopharm International SA Priority pathogens Acinetobacter baumannii Critical priority pathogens No Yes Yes NA NA WHO AMR pipeline analysis Nov-21 ALS-4 - Non-traditional Miscellaneous Staphyloxanthin biosynthesis inhibition S. aureus Oral Phase I Not registered Aptorum Group Priority pathogens Streptococcus pneumoniae Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 ALS-4 - Non-traditional Miscellaneous Staphyloxanthin biosynthesis inhibition S. aureus Oral Phase I Not registered Aptorum Group Priority pathogens Staphylococcus aureus Other priority pathogens Yes N/A Yes NA NA WHO AMR pipeline analysis Nov-21 ALS-4 - Non-traditional Miscellaneous Staphyloxanthin biosynthesis inhibition S. aureus Oral Phase I Not registered Aptorum Group Priority pathogens Pseudomonas aeruginosa Critical priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 ALS-4 - Non-traditional Miscellaneous Staphyloxanthin biosynthesis inhibition S. aureus Oral Phase I Not registered Aptorum Group Priority pathogens Other priority pathogens Other priority pathogens Yes N/A Yes NA NA WHO AMR pipeline analysis Nov-21 ALS-4 - Non-traditional Miscellaneous Staphyloxanthin biosynthesis inhibition S. aureus Oral Phase I Not registered Aptorum Group Priority pathogens Neisseria gonnorhoeae Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 ALS-4 - Non-traditional Miscellaneous Staphyloxanthin biosynthesis inhibition S. aureus Oral Phase I Not registered Aptorum Group Priority pathogens Helicobacter pylori Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 ALS-4 - Non-traditional Miscellaneous Staphyloxanthin biosynthesis inhibition S. aureus Oral Phase I Not registered Aptorum Group Priority pathogens Gram-positive priority pathogens Other priority pathogens Yes N/A Yes NA NA WHO AMR pipeline analysis Nov-21 ALS-4 - Non-traditional Miscellaneous Staphyloxanthin biosynthesis inhibition S. aureus Oral Phase I Not registered Aptorum Group Priority pathogens Enterococcus faecium Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 ALS-4 - Non-traditional Miscellaneous Staphyloxanthin biosynthesis inhibition S. aureus Oral Phase I Not registered Aptorum Group Priority pathogens Enterobacterales Critical priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 ALS-4 - Non-traditional Miscellaneous Staphyloxanthin biosynthesis inhibition S. aureus Oral Phase I Not registered Aptorum Group Priority pathogens Critical priority pathogens Critical priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 ALS-4 - Non-traditional Miscellaneous Staphyloxanthin biosynthesis inhibition S. aureus Oral Phase I Not registered Aptorum Group Priority pathogens Campylobacter spp. Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 ALS-4 - Non-traditional Miscellaneous Staphyloxanthin biosynthesis inhibition S. aureus Oral Phase I Not registered Aptorum Group Priority pathogens All critical priority pathogens Critical priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 ALS-4 - Non-traditional Miscellaneous Staphyloxanthin biosynthesis inhibition S. aureus Oral Phase I Not registered Aptorum Group Priority pathogens Acinetobacter baumannii Critical priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 AP-PA02 - Non-traditional Bacteriophages and phage-derived enzymes Bacteriophage CF subjects with P. aeruginosa infections Inhalation Phase II NCT04596319 Armata Pharmaceuticals Priority pathogens Streptococcus pneumoniae Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 AP-PA02 - Non-traditional Bacteriophages and phage-derived enzymes Bacteriophage CF subjects with P. aeruginosa infections Inhalation Phase II NCT04596319 Armata Pharmaceuticals Priority pathogens Staphylococcus aureus Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 AP-PA02 - Non-traditional Bacteriophages and phage-derived enzymes Bacteriophage CF subjects with P. aeruginosa infections Inhalation Phase II NCT04596319 Armata Pharmaceuticals Priority pathogens Pseudomonas aeruginosa Critical priority pathogens Yes N/A Yes NA NA WHO AMR pipeline analysis Nov-21 AP-PA02 - Non-traditional Bacteriophages and phage-derived enzymes Bacteriophage CF subjects with P. aeruginosa infections Inhalation Phase II NCT04596319 Armata Pharmaceuticals Priority pathogens Other priority pathogens Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 AP-PA02 - Non-traditional Bacteriophages and phage-derived enzymes Bacteriophage CF subjects with P. aeruginosa infections Inhalation Phase II NCT04596319 Armata Pharmaceuticals Priority pathogens Neisseria gonnorhoeae Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 AP-PA02 - Non-traditional Bacteriophages and phage-derived enzymes Bacteriophage CF subjects with P. aeruginosa infections Inhalation Phase II NCT04596319 Armata Pharmaceuticals Priority pathogens Helicobacter pylori Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 AP-PA02 - Non-traditional Bacteriophages and phage-derived enzymes Bacteriophage CF subjects with P. aeruginosa infections Inhalation Phase II NCT04596319 Armata Pharmaceuticals Priority pathogens Gram-positive priority pathogens Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 AP-PA02 - Non-traditional Bacteriophages and phage-derived enzymes Bacteriophage CF subjects with P. aeruginosa infections Inhalation Phase II NCT04596319 Armata Pharmaceuticals Priority pathogens Enterococcus faecium Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 AP-PA02 - Non-traditional Bacteriophages and phage-derived enzymes Bacteriophage CF subjects with P. aeruginosa infections Inhalation Phase II NCT04596319 Armata Pharmaceuticals Priority pathogens Enterobacterales Critical priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 AP-PA02 - Non-traditional Bacteriophages and phage-derived enzymes Bacteriophage CF subjects with P. aeruginosa infections Inhalation Phase II NCT04596319 Armata Pharmaceuticals Priority pathogens Critical priority pathogens Critical priority pathogens Yes N/A Yes NA NA WHO AMR pipeline analysis Nov-21 AP-PA02 - Non-traditional Bacteriophages and phage-derived enzymes Bacteriophage CF subjects with P. aeruginosa infections Inhalation Phase II NCT04596319 Armata Pharmaceuticals Priority pathogens Campylobacter spp. Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 AP-PA02 - Non-traditional Bacteriophages and phage-derived enzymes Bacteriophage CF subjects with P. aeruginosa infections Inhalation Phase II NCT04596319 Armata Pharmaceuticals Priority pathogens All critical priority pathogens Critical priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 AP-PA02 - Non-traditional Bacteriophages and phage-derived enzymes Bacteriophage CF subjects with P. aeruginosa infections Inhalation Phase II NCT04596319 Armata Pharmaceuticals Priority pathogens Acinetobacter baumannii Critical priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 AR-301 Tosatoxumab Non-traditional Antibodies anti-S. aureus IgM monoclonal Ab S. aureus HAP, VAP IV Phase III NCT03816956 Aridis Pharmaceuticals, Inc. Priority pathogens Streptococcus pneumoniae Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 AR-301 Tosatoxumab Non-traditional Antibodies anti-S. aureus IgM monoclonal Ab S. aureus HAP, VAP IV Phase III NCT03816956 Aridis Pharmaceuticals, Inc. Priority pathogens Staphylococcus aureus Other priority pathogens Yes N/A Yes NA NA WHO AMR pipeline analysis Nov-21 AR-301 Tosatoxumab Non-traditional Antibodies anti-S. aureus IgM monoclonal Ab S. aureus HAP, VAP IV Phase III NCT03816956 Aridis Pharmaceuticals, Inc. Priority pathogens Pseudomonas aeruginosa Critical priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 AR-301 Tosatoxumab Non-traditional Antibodies anti-S. aureus IgM monoclonal Ab S. aureus HAP, VAP IV Phase III NCT03816956 Aridis Pharmaceuticals, Inc. Priority pathogens Other priority pathogens Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 AR-301 Tosatoxumab Non-traditional Antibodies anti-S. aureus IgM monoclonal Ab S. aureus HAP, VAP IV Phase III NCT03816956 Aridis Pharmaceuticals, Inc. Priority pathogens Neisseria gonnorhoeae Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 AR-301 Tosatoxumab Non-traditional Antibodies anti-S. aureus IgM monoclonal Ab S. aureus HAP, VAP IV Phase III NCT03816956 Aridis Pharmaceuticals, Inc. Priority pathogens Helicobacter pylori Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 AR-301 Tosatoxumab Non-traditional Antibodies anti-S. aureus IgM monoclonal Ab S. aureus HAP, VAP IV Phase III NCT03816956 Aridis Pharmaceuticals, Inc. Priority pathogens Gram-positive priority pathogens Other priority pathogens Yes N/A Yes NA NA WHO AMR pipeline analysis Nov-21 AR-301 Tosatoxumab Non-traditional Antibodies anti-S. aureus IgM monoclonal Ab S. aureus HAP, VAP IV Phase III NCT03816956 Aridis Pharmaceuticals, Inc. Priority pathogens Enterococcus faecium Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 AR-301 Tosatoxumab Non-traditional Antibodies anti-S. aureus IgM monoclonal Ab S. aureus HAP, VAP IV Phase III NCT03816956 Aridis Pharmaceuticals, Inc. Priority pathogens Enterobacterales Critical priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 AR-301 Tosatoxumab Non-traditional Antibodies anti-S. aureus IgM monoclonal Ab S. aureus HAP, VAP IV Phase III NCT03816956 Aridis Pharmaceuticals, Inc. Priority pathogens Critical priority pathogens Critical priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 AR-301 Tosatoxumab Non-traditional Antibodies anti-S. aureus IgM monoclonal Ab S. aureus HAP, VAP IV Phase III NCT03816956 Aridis Pharmaceuticals, Inc. Priority pathogens Campylobacter spp. Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 AR-301 Tosatoxumab Non-traditional Antibodies anti-S. aureus IgM monoclonal Ab S. aureus HAP, VAP IV Phase III NCT03816956 Aridis Pharmaceuticals, Inc. Priority pathogens All critical priority pathogens Critical priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 AR-301 Tosatoxumab Non-traditional Antibodies anti-S. aureus IgM monoclonal Ab S. aureus HAP, VAP IV Phase III NCT03816956 Aridis Pharmaceuticals, Inc. Priority pathogens Acinetobacter baumannii Critical priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 AR-302 MEDI-4893, Suvratoxumab Non-traditional Antibodies anti-S. aureus IgG monoclonal Ab S. aureus HAP, VAP IV Phase II NCT02296320 "Aridis AstraZeneca/ MedImmune" Priority pathogens Streptococcus pneumoniae Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 AR-302 MEDI-4893, Suvratoxumab Non-traditional Antibodies anti-S. aureus IgG monoclonal Ab S. aureus HAP, VAP IV Phase II NCT02296320 "Aridis AstraZeneca/ MedImmune" Priority pathogens Staphylococcus aureus Other priority pathogens Yes N/A Yes NA NA WHO AMR pipeline analysis Nov-21 AR-302 MEDI-4893, Suvratoxumab Non-traditional Antibodies anti-S. aureus IgG monoclonal Ab S. aureus HAP, VAP IV Phase II NCT02296320 "Aridis AstraZeneca/ MedImmune" Priority pathogens Pseudomonas aeruginosa Critical priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 AR-302 MEDI-4893, Suvratoxumab Non-traditional Antibodies anti-S. aureus IgG monoclonal Ab S. aureus HAP, VAP IV Phase II NCT02296320 "Aridis AstraZeneca/ MedImmune" Priority pathogens Other priority pathogens Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 AR-302 MEDI-4893, Suvratoxumab Non-traditional Antibodies anti-S. aureus IgG monoclonal Ab S. aureus HAP, VAP IV Phase II NCT02296320 "Aridis AstraZeneca/ MedImmune" Priority pathogens Neisseria gonnorhoeae Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 AR-302 MEDI-4893, Suvratoxumab Non-traditional Antibodies anti-S. aureus IgG monoclonal Ab S. aureus HAP, VAP IV Phase II NCT02296320 "Aridis AstraZeneca/ MedImmune" Priority pathogens Helicobacter pylori Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 AR-302 MEDI-4893, Suvratoxumab Non-traditional Antibodies anti-S. aureus IgG monoclonal Ab S. aureus HAP, VAP IV Phase II NCT02296320 "Aridis AstraZeneca/ MedImmune" Priority pathogens Gram-positive priority pathogens Other priority pathogens Yes N/A Yes NA NA WHO AMR pipeline analysis Nov-21 AR-302 MEDI-4893, Suvratoxumab Non-traditional Antibodies anti-S. aureus IgG monoclonal Ab S. aureus HAP, VAP IV Phase II NCT02296320 "Aridis AstraZeneca/ MedImmune" Priority pathogens Enterococcus faecium Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 AR-302 MEDI-4893, Suvratoxumab Non-traditional Antibodies anti-S. aureus IgG monoclonal Ab S. aureus HAP, VAP IV Phase II NCT02296320 "Aridis AstraZeneca/ MedImmune" Priority pathogens Enterobacterales Critical priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 AR-302 MEDI-4893, Suvratoxumab Non-traditional Antibodies anti-S. aureus IgG monoclonal Ab S. aureus HAP, VAP IV Phase II NCT02296320 "Aridis AstraZeneca/ MedImmune" Priority pathogens Critical priority pathogens Critical priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 AR-302 MEDI-4893, Suvratoxumab Non-traditional Antibodies anti-S. aureus IgG monoclonal Ab S. aureus HAP, VAP IV Phase II NCT02296320 "Aridis AstraZeneca/ MedImmune" Priority pathogens Campylobacter spp. Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 AR-302 MEDI-4893, Suvratoxumab Non-traditional Antibodies anti-S. aureus IgG monoclonal Ab S. aureus HAP, VAP IV Phase II NCT02296320 "Aridis AstraZeneca/ MedImmune" Priority pathogens All critical priority pathogens Critical priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 AR-302 MEDI-4893, Suvratoxumab Non-traditional Antibodies anti-S. aureus IgG monoclonal Ab S. aureus HAP, VAP IV Phase II NCT02296320 "Aridis AstraZeneca/ MedImmune" Priority pathogens Acinetobacter baumannii Critical priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 ARX-1796 Oral Avibactam prodrug Antibiotics NA DBO-BLI + β-lactam Gram-negative infections Oral Phase I NCT03931876 Pfizer/ Arixa Pharmaceuticals Priority pathogens Streptococcus pneumoniae Other priority pathogens No No Yes NA NA WHO AMR pipeline analysis Nov-21 ARX-1796 Oral Avibactam prodrug Antibiotics NA DBO-BLI + β-lactam Gram-negative infections Oral Phase I NCT03931876 Pfizer/ Arixa Pharmaceuticals Priority pathogens Staphylococcus aureus Other priority pathogens No No Yes NA NA WHO AMR pipeline analysis Nov-21 ARX-1796 Oral Avibactam prodrug Antibiotics NA DBO-BLI + β-lactam Gram-negative infections Oral Phase I NCT03931876 Pfizer/ Arixa Pharmaceuticals Priority pathogens Pseudomonas aeruginosa Critical priority pathogens Possibly No Yes NA NA WHO AMR pipeline analysis Nov-21 ARX-1796 Oral Avibactam prodrug Antibiotics NA DBO-BLI + β-lactam Gram-negative infections Oral Phase I NCT03931876 Pfizer/ Arixa Pharmaceuticals Priority pathogens Other priority pathogens Other priority pathogens No No Yes NA NA WHO AMR pipeline analysis Nov-21 ARX-1796 Oral Avibactam prodrug Antibiotics NA DBO-BLI + β-lactam Gram-negative infections Oral Phase I NCT03931876 Pfizer/ Arixa Pharmaceuticals Priority pathogens Neisseria gonnorhoeae Other priority pathogens No No Yes NA NA WHO AMR pipeline analysis Nov-21 ARX-1796 Oral Avibactam prodrug Antibiotics NA DBO-BLI + β-lactam Gram-negative infections Oral Phase I NCT03931876 Pfizer/ Arixa Pharmaceuticals Priority pathogens Helicobacter pylori Other priority pathogens No No Yes NA NA WHO AMR pipeline analysis Nov-21 ARX-1796 Oral Avibactam prodrug Antibiotics NA DBO-BLI + β-lactam Gram-negative infections Oral Phase I NCT03931876 Pfizer/ Arixa Pharmaceuticals Priority pathogens Gram-positive priority pathogens Other priority pathogens No No Yes NA NA WHO AMR pipeline analysis Nov-21 ARX-1796 Oral Avibactam prodrug Antibiotics NA DBO-BLI + β-lactam Gram-negative infections Oral Phase I NCT03931876 Pfizer/ Arixa Pharmaceuticals Priority pathogens Enterococcus faecium Other priority pathogens No No Yes NA NA WHO AMR pipeline analysis Nov-21 ARX-1796 Oral Avibactam prodrug Antibiotics NA DBO-BLI + β-lactam Gram-negative infections Oral Phase I NCT03931876 Pfizer/ Arixa Pharmaceuticals Priority pathogens Enterobacterales Critical priority pathogens Yes No Yes NA NA WHO AMR pipeline analysis Nov-21 ARX-1796 Oral Avibactam prodrug Antibiotics NA DBO-BLI + β-lactam Gram-negative infections Oral Phase I NCT03931876 Pfizer/ Arixa Pharmaceuticals Priority pathogens Critical priority pathogens Critical priority pathogens Yes No Yes NA NA WHO AMR pipeline analysis Nov-21 ARX-1796 Oral Avibactam prodrug Antibiotics NA DBO-BLI + β-lactam Gram-negative infections Oral Phase I NCT03931876 Pfizer/ Arixa Pharmaceuticals Priority pathogens Campylobacter spp. Other priority pathogens No No Yes NA NA WHO AMR pipeline analysis Nov-21 ARX-1796 Oral Avibactam prodrug Antibiotics NA DBO-BLI + β-lactam Gram-negative infections Oral Phase I NCT03931876 Pfizer/ Arixa Pharmaceuticals Priority pathogens All critical priority pathogens Critical priority pathogens No No Yes NA NA WHO AMR pipeline analysis Nov-21 ARX-1796 Oral Avibactam prodrug Antibiotics NA DBO-BLI + β-lactam Gram-negative infections Oral Phase I NCT03931876 Pfizer/ Arixa Pharmaceuticals Priority pathogens Acinetobacter baumannii Critical priority pathogens Possibly No Yes NA NA WHO AMR pipeline analysis Nov-21 Benapenem - Antibiotics NA Carbapenem cUTI IV Phase III NCT03578588, CTR20190760, CTR20181302 Sichuan Pharmaceutical Holdings Group Ltd Priority pathogens Streptococcus pneumoniae Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 Benapenem - Antibiotics NA Carbapenem cUTI IV Phase III NCT03578588, CTR20190760, CTR20181302 Sichuan Pharmaceutical Holdings Group Ltd Priority pathogens Staphylococcus aureus Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 Benapenem - Antibiotics NA Carbapenem cUTI IV Phase III NCT03578588, CTR20190760, CTR20181302 Sichuan Pharmaceutical Holdings Group Ltd Priority pathogens Pseudomonas aeruginosa Critical priority pathogens Possibly No Yes NA NA WHO AMR pipeline analysis Nov-21 Benapenem - Antibiotics NA Carbapenem cUTI IV Phase III NCT03578588, CTR20190760, CTR20181302 Sichuan Pharmaceutical Holdings Group Ltd Priority pathogens Other priority pathogens Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 Benapenem - Antibiotics NA Carbapenem cUTI IV Phase III NCT03578588, CTR20190760, CTR20181302 Sichuan Pharmaceutical Holdings Group Ltd Priority pathogens Neisseria gonnorhoeae Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 Benapenem - Antibiotics NA Carbapenem cUTI IV Phase III NCT03578588, CTR20190760, CTR20181302 Sichuan Pharmaceutical Holdings Group Ltd Priority pathogens Helicobacter pylori Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 Benapenem - Antibiotics NA Carbapenem cUTI IV Phase III NCT03578588, CTR20190760, CTR20181302 Sichuan Pharmaceutical Holdings Group Ltd Priority pathogens Gram-positive priority pathogens Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 Benapenem - Antibiotics NA Carbapenem cUTI IV Phase III NCT03578588, CTR20190760, CTR20181302 Sichuan Pharmaceutical Holdings Group Ltd Priority pathogens Enterococcus faecium Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 Benapenem - Antibiotics NA Carbapenem cUTI IV Phase III NCT03578588, CTR20190760, CTR20181302 Sichuan Pharmaceutical Holdings Group Ltd Priority pathogens Enterobacterales Critical priority pathogens Possibly No Yes NA NA WHO AMR pipeline analysis Nov-21 Benapenem - Antibiotics NA Carbapenem cUTI IV Phase III NCT03578588, CTR20190760, CTR20181302 Sichuan Pharmaceutical Holdings Group Ltd Priority pathogens Critical priority pathogens Critical priority pathogens Yes No Yes NA NA WHO AMR pipeline analysis Nov-21 Benapenem - Antibiotics NA Carbapenem cUTI IV Phase III NCT03578588, CTR20190760, CTR20181302 Sichuan Pharmaceutical Holdings Group Ltd Priority pathogens Campylobacter spp. Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 Benapenem - Antibiotics NA Carbapenem cUTI IV Phase III NCT03578588, CTR20190760, CTR20181302 Sichuan Pharmaceutical Holdings Group Ltd Priority pathogens All critical priority pathogens Critical priority pathogens No No Yes NA NA WHO AMR pipeline analysis Nov-21 Benapenem - Antibiotics NA Carbapenem cUTI IV Phase III NCT03578588, CTR20190760, CTR20181302 Sichuan Pharmaceutical Holdings Group Ltd Priority pathogens Acinetobacter baumannii Critical priority pathogens Possibly No Yes NA NA WHO AMR pipeline analysis Nov-21 BWC0977 Antibiotics NA Topoisomerase Gram-negative and Gram-positive bacterial infections IV Phase I NCT05088421 Bugworks Research Priority pathogens Streptococcus pneumoniae Other priority pathogens Yes Inconclusive Yes NA NA WHO AMR pipeline analysis Nov-21 BWC0977 Antibiotics NA Topoisomerase Gram-negative and Gram-positive bacterial infections IV Phase I NCT05088421 Bugworks Research Priority pathogens Staphylococcus aureus Other priority pathogens Yes Inconclusive Yes NA NA WHO AMR pipeline analysis Nov-21 BWC0977 Antibiotics NA Topoisomerase Gram-negative and Gram-positive bacterial infections IV Phase I NCT05088421 Bugworks Research Priority pathogens Pseudomonas aeruginosa Critical priority pathogens Possibly Inconclusive Yes NA NA WHO AMR pipeline analysis Nov-21 BWC0977 Antibiotics NA Topoisomerase Gram-negative and Gram-positive bacterial infections IV Phase I NCT05088421 Bugworks Research Priority pathogens Other priority pathogens Other priority pathogens Yes Inconclusive Yes NA NA WHO AMR pipeline analysis Nov-21 BWC0977 Antibiotics NA Topoisomerase Gram-negative and Gram-positive bacterial infections IV Phase I NCT05088421 Bugworks Research Priority pathogens Neisseria gonnorhoeae Other priority pathogens N/A Inconclusive Yes NA NA WHO AMR pipeline analysis Nov-21 BWC0977 Antibiotics NA Topoisomerase Gram-negative and Gram-positive bacterial infections IV Phase I NCT05088421 Bugworks Research Priority pathogens Helicobacter pylori Other priority pathogens N/A Inconclusive Yes NA NA WHO AMR pipeline analysis Nov-21 BWC0977 Antibiotics NA Topoisomerase Gram-negative and Gram-positive bacterial infections IV Phase I NCT05088421 Bugworks Research Priority pathogens Gram-positive priority pathogens Other priority pathogens Yes Inconclusive Yes NA NA WHO AMR pipeline analysis Nov-21 BWC0977 Antibiotics NA Topoisomerase Gram-negative and Gram-positive bacterial infections IV Phase I NCT05088421 Bugworks Research Priority pathogens Enterococcus faecium Other priority pathogens Yes Inconclusive Yes NA NA WHO AMR pipeline analysis Nov-21 BWC0977 Antibiotics NA Topoisomerase Gram-negative and Gram-positive bacterial infections IV Phase I NCT05088421 Bugworks Research Priority pathogens Enterobacterales Critical priority pathogens Possibly Inconclusive Yes NA NA WHO AMR pipeline analysis Nov-21 BWC0977 Antibiotics NA Topoisomerase Gram-negative and Gram-positive bacterial infections IV Phase I NCT05088421 Bugworks Research Priority pathogens Critical priority pathogens Critical priority pathogens Possibly Inconclusive Yes NA NA WHO AMR pipeline analysis Nov-21 BWC0977 Antibiotics NA Topoisomerase Gram-negative and Gram-positive bacterial infections IV Phase I NCT05088421 Bugworks Research Priority pathogens Campylobacter spp. Other priority pathogens N/A Inconclusive Yes NA NA WHO AMR pipeline analysis Nov-21 BWC0977 Antibiotics NA Topoisomerase Gram-negative and Gram-positive bacterial infections IV Phase I NCT05088421 Bugworks Research Priority pathogens All critical priority pathogens Critical priority pathogens Yes Inconclusive Yes NA NA WHO AMR pipeline analysis Nov-21 BWC0977 Antibiotics NA Topoisomerase Gram-negative and Gram-positive bacterial infections IV Phase I NCT05088421 Bugworks Research Priority pathogens Acinetobacter baumannii Critical priority pathogens Possibly Inconclusive Yes NA NA WHO AMR pipeline analysis Nov-21 BX004-A - Non-traditional Bacteriophages and phage-derived enzymes Bacteriophage CF subjects with P. aeruginosa infections Inhalation Phase II NCT05010577 BiomX Priority pathogens Streptococcus pneumoniae Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 BX004-A - Non-traditional Bacteriophages and phage-derived enzymes Bacteriophage CF subjects with P. aeruginosa infections Inhalation Phase II NCT05010577 BiomX Priority pathogens Staphylococcus aureus Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 BX004-A - Non-traditional Bacteriophages and phage-derived enzymes Bacteriophage CF subjects with P. aeruginosa infections Inhalation Phase II NCT05010577 BiomX Priority pathogens Pseudomonas aeruginosa Critical priority pathogens Yes N/A Yes NA NA WHO AMR pipeline analysis Nov-21 BX004-A - Non-traditional Bacteriophages and phage-derived enzymes Bacteriophage CF subjects with P. aeruginosa infections Inhalation Phase II NCT05010577 BiomX Priority pathogens Other priority pathogens Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 BX004-A - Non-traditional Bacteriophages and phage-derived enzymes Bacteriophage CF subjects with P. aeruginosa infections Inhalation Phase II NCT05010577 BiomX Priority pathogens Neisseria gonnorhoeae Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 BX004-A - Non-traditional Bacteriophages and phage-derived enzymes Bacteriophage CF subjects with P. aeruginosa infections Inhalation Phase II NCT05010577 BiomX Priority pathogens Helicobacter pylori Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 BX004-A - Non-traditional Bacteriophages and phage-derived enzymes Bacteriophage CF subjects with P. aeruginosa infections Inhalation Phase II NCT05010577 BiomX Priority pathogens Gram-positive priority pathogens Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 BX004-A - Non-traditional Bacteriophages and phage-derived enzymes Bacteriophage CF subjects with P. aeruginosa infections Inhalation Phase II NCT05010577 BiomX Priority pathogens Enterococcus faecium Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 BX004-A - Non-traditional Bacteriophages and phage-derived enzymes Bacteriophage CF subjects with P. aeruginosa infections Inhalation Phase II NCT05010577 BiomX Priority pathogens Enterobacterales Critical priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 BX004-A - Non-traditional Bacteriophages and phage-derived enzymes Bacteriophage CF subjects with P. aeruginosa infections Inhalation Phase II NCT05010577 BiomX Priority pathogens Critical priority pathogens Critical priority pathogens Yes N/A Yes NA NA WHO AMR pipeline analysis Nov-21 BX004-A - Non-traditional Bacteriophages and phage-derived enzymes Bacteriophage CF subjects with P. aeruginosa infections Inhalation Phase II NCT05010577 BiomX Priority pathogens Campylobacter spp. Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 BX004-A - Non-traditional Bacteriophages and phage-derived enzymes Bacteriophage CF subjects with P. aeruginosa infections Inhalation Phase II NCT05010577 BiomX Priority pathogens All critical priority pathogens Critical priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 BX004-A - Non-traditional Bacteriophages and phage-derived enzymes Bacteriophage CF subjects with P. aeruginosa infections Inhalation Phase II NCT05010577 BiomX Priority pathogens Acinetobacter baumannii Critical priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 CAL02 - Non-traditional Miscellaneous Broad spectrum anti-toxin liposomal agent and nanoparticle S. pneumonia severe pneumonia IV Phase I NCT02583373 "Eagle Pharmaceuticals (Combioxin SA)" Priority pathogens Streptococcus pneumoniae Other priority pathogens Yes N/A Yes NA NA WHO AMR pipeline analysis Nov-21 CAL02 - Non-traditional Miscellaneous Broad spectrum anti-toxin liposomal agent and nanoparticle S. pneumonia severe pneumonia IV Phase I NCT02583373 "Eagle Pharmaceuticals (Combioxin SA)" Priority pathogens Staphylococcus aureus Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 CAL02 - Non-traditional Miscellaneous Broad spectrum anti-toxin liposomal agent and nanoparticle S. pneumonia severe pneumonia IV Phase I NCT02583373 "Eagle Pharmaceuticals (Combioxin SA)" Priority pathogens Pseudomonas aeruginosa Critical priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 CAL02 - Non-traditional Miscellaneous Broad spectrum anti-toxin liposomal agent and nanoparticle S. pneumonia severe pneumonia IV Phase I NCT02583373 "Eagle Pharmaceuticals (Combioxin SA)" Priority pathogens Other priority pathogens Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 CAL02 - Non-traditional Miscellaneous Broad spectrum anti-toxin liposomal agent and nanoparticle S. pneumonia severe pneumonia IV Phase I NCT02583373 "Eagle Pharmaceuticals (Combioxin SA)" Priority pathogens Neisseria gonnorhoeae Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 CAL02 - Non-traditional Miscellaneous Broad spectrum anti-toxin liposomal agent and nanoparticle S. pneumonia severe pneumonia IV Phase I NCT02583373 "Eagle Pharmaceuticals (Combioxin SA)" Priority pathogens Helicobacter pylori Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 CAL02 - Non-traditional Miscellaneous Broad spectrum anti-toxin liposomal agent and nanoparticle S. pneumonia severe pneumonia IV Phase I NCT02583373 "Eagle Pharmaceuticals (Combioxin SA)" Priority pathogens Gram-positive priority pathogens Other priority pathogens Yes N/A Yes NA NA WHO AMR pipeline analysis Nov-21 CAL02 - Non-traditional Miscellaneous Broad spectrum anti-toxin liposomal agent and nanoparticle S. pneumonia severe pneumonia IV Phase I NCT02583373 "Eagle Pharmaceuticals (Combioxin SA)" Priority pathogens Enterococcus faecium Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 CAL02 - Non-traditional Miscellaneous Broad spectrum anti-toxin liposomal agent and nanoparticle S. pneumonia severe pneumonia IV Phase I NCT02583373 "Eagle Pharmaceuticals (Combioxin SA)" Priority pathogens Enterobacterales Critical priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 CAL02 - Non-traditional Miscellaneous Broad spectrum anti-toxin liposomal agent and nanoparticle S. pneumonia severe pneumonia IV Phase I NCT02583373 "Eagle Pharmaceuticals (Combioxin SA)" Priority pathogens Critical priority pathogens Critical priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 CAL02 - Non-traditional Miscellaneous Broad spectrum anti-toxin liposomal agent and nanoparticle S. pneumonia severe pneumonia IV Phase I NCT02583373 "Eagle Pharmaceuticals (Combioxin SA)" Priority pathogens Campylobacter spp. Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 CAL02 - Non-traditional Miscellaneous Broad spectrum anti-toxin liposomal agent and nanoparticle S. pneumonia severe pneumonia IV Phase I NCT02583373 "Eagle Pharmaceuticals (Combioxin SA)" Priority pathogens All critical priority pathogens Critical priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 CAL02 - Non-traditional Miscellaneous Broad spectrum anti-toxin liposomal agent and nanoparticle S. pneumonia severe pneumonia IV Phase I NCT02583373 "Eagle Pharmaceuticals (Combioxin SA)" Priority pathogens Acinetobacter baumannii Critical priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 CF-301 Exebacase Non-traditional Bacteriophages and phage-derived enzymes Phage endolysin S. aureus bacteremia IV Phase III NCT04160468 Contrafect Priority pathogens Streptococcus pneumoniae Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 CF-301 Exebacase Non-traditional Bacteriophages and phage-derived enzymes Phage endolysin S. aureus bacteremia IV Phase III NCT04160468 Contrafect Priority pathogens Staphylococcus aureus Other priority pathogens Yes N/A Yes NA NA WHO AMR pipeline analysis Nov-21 CF-301 Exebacase Non-traditional Bacteriophages and phage-derived enzymes Phage endolysin S. aureus bacteremia IV Phase III NCT04160468 Contrafect Priority pathogens Pseudomonas aeruginosa Critical priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 CF-301 Exebacase Non-traditional Bacteriophages and phage-derived enzymes Phage endolysin S. aureus bacteremia IV Phase III NCT04160468 Contrafect Priority pathogens Other priority pathogens Other priority pathogens Yes N/A Yes NA NA WHO AMR pipeline analysis Nov-21 CF-301 Exebacase Non-traditional Bacteriophages and phage-derived enzymes Phage endolysin S. aureus bacteremia IV Phase III NCT04160468 Contrafect Priority pathogens Neisseria gonnorhoeae Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 CF-301 Exebacase Non-traditional Bacteriophages and phage-derived enzymes Phage endolysin S. aureus bacteremia IV Phase III NCT04160468 Contrafect Priority pathogens Helicobacter pylori Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 CF-301 Exebacase Non-traditional Bacteriophages and phage-derived enzymes Phage endolysin S. aureus bacteremia IV Phase III NCT04160468 Contrafect Priority pathogens Gram-positive priority pathogens Other priority pathogens Yes N/A Yes NA NA WHO AMR pipeline analysis Nov-21 CF-301 Exebacase Non-traditional Bacteriophages and phage-derived enzymes Phage endolysin S. aureus bacteremia IV Phase III NCT04160468 Contrafect Priority pathogens Enterococcus faecium Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 CF-301 Exebacase Non-traditional Bacteriophages and phage-derived enzymes Phage endolysin S. aureus bacteremia IV Phase III NCT04160468 Contrafect Priority pathogens Enterobacterales Critical priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 CF-301 Exebacase Non-traditional Bacteriophages and phage-derived enzymes Phage endolysin S. aureus bacteremia IV Phase III NCT04160468 Contrafect Priority pathogens Critical priority pathogens Critical priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 CF-301 Exebacase Non-traditional Bacteriophages and phage-derived enzymes Phage endolysin S. aureus bacteremia IV Phase III NCT04160468 Contrafect Priority pathogens Campylobacter spp. Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 CF-301 Exebacase Non-traditional Bacteriophages and phage-derived enzymes Phage endolysin S. aureus bacteremia IV Phase III NCT04160468 Contrafect Priority pathogens All critical priority pathogens Critical priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 CF-301 Exebacase Non-traditional Bacteriophages and phage-derived enzymes Phage endolysin S. aureus bacteremia IV Phase III NCT04160468 Contrafect Priority pathogens Acinetobacter baumannii Critical priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 Delpazolid LCB01-0371 Antibiotics NA Oxazolidinone Pulmonary tuberculosis, Gram-positive bacterial infections Oral Phase II NCT02836483, NCT04550832 LegoChem Biosciences Inc., HaiHe Biopharma Priority pathogens Staphylococcus aureus Other priority pathogens Yes No Yes y NA WHO AMR pipeline analysis Nov-21 Durlobactam + sulbactam ETX2514 Antibiotics NA DBO-BLI /PBP2 binder + β-lactam-BLI/PBP1,3 binder A. baumannii HAP, VAP IV Phase III NCT03445195, NCT03894046 Entasis Therapeutics Inc. Priority pathogens Streptococcus pneumoniae Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 Durlobactam + sulbactam ETX2514 Antibiotics NA DBO-BLI /PBP2 binder + β-lactam-BLI/PBP1,3 binder A. baumannii HAP, VAP IV Phase III NCT03445195, NCT03894046 Entasis Therapeutics Inc. Priority pathogens Staphylococcus aureus Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 Durlobactam + sulbactam ETX2514 Antibiotics NA DBO-BLI /PBP2 binder + β-lactam-BLI/PBP1,3 binder A. baumannii HAP, VAP IV Phase III NCT03445195, NCT03894046 Entasis Therapeutics Inc. Priority pathogens Pseudomonas aeruginosa Critical priority pathogens Possibly No Yes NA NA WHO AMR pipeline analysis Nov-21 Durlobactam + sulbactam ETX2514 Antibiotics NA DBO-BLI /PBP2 binder + β-lactam-BLI/PBP1,3 binder A. baumannii HAP, VAP IV Phase III NCT03445195, NCT03894046 Entasis Therapeutics Inc. Priority pathogens Other priority pathogens Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 Durlobactam + sulbactam ETX2514 Antibiotics NA DBO-BLI /PBP2 binder + β-lactam-BLI/PBP1,3 binder A. baumannii HAP, VAP IV Phase III NCT03445195, NCT03894046 Entasis Therapeutics Inc. Priority pathogens Neisseria gonnorhoeae Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 Durlobactam + sulbactam ETX2514 Antibiotics NA DBO-BLI /PBP2 binder + β-lactam-BLI/PBP1,3 binder A. baumannii HAP, VAP IV Phase III NCT03445195, NCT03894046 Entasis Therapeutics Inc. Priority pathogens Helicobacter pylori Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 Durlobactam + sulbactam ETX2514 Antibiotics NA DBO-BLI /PBP2 binder + β-lactam-BLI/PBP1,3 binder A. baumannii HAP, VAP IV Phase III NCT03445195, NCT03894046 Entasis Therapeutics Inc. Priority pathogens Gram-positive priority pathogens Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 Durlobactam + sulbactam ETX2514 Antibiotics NA DBO-BLI /PBP2 binder + β-lactam-BLI/PBP1,3 binder A. baumannii HAP, VAP IV Phase III NCT03445195, NCT03894046 Entasis Therapeutics Inc. Priority pathogens Enterococcus faecium Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 Durlobactam + sulbactam ETX2514 Antibiotics NA DBO-BLI /PBP2 binder + β-lactam-BLI/PBP1,3 binder A. baumannii HAP, VAP IV Phase III NCT03445195, NCT03894046 Entasis Therapeutics Inc. Priority pathogens Enterobacterales Critical priority pathogens Possibly No Yes NA NA WHO AMR pipeline analysis Nov-21 Durlobactam + sulbactam ETX2514 Antibiotics NA DBO-BLI /PBP2 binder + β-lactam-BLI/PBP1,3 binder A. baumannii HAP, VAP IV Phase III NCT03445195, NCT03894046 Entasis Therapeutics Inc. Priority pathogens Critical priority pathogens Critical priority pathogens Yes No Yes NA NA WHO AMR pipeline analysis Nov-21 Durlobactam + sulbactam ETX2514 Antibiotics NA DBO-BLI /PBP2 binder + β-lactam-BLI/PBP1,3 binder A. baumannii HAP, VAP IV Phase III NCT03445195, NCT03894046 Entasis Therapeutics Inc. Priority pathogens Campylobacter spp. Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 Durlobactam + sulbactam ETX2514 Antibiotics NA DBO-BLI /PBP2 binder + β-lactam-BLI/PBP1,3 binder A. baumannii HAP, VAP IV Phase III NCT03445195, NCT03894046 Entasis Therapeutics Inc. Priority pathogens All critical priority pathogens Critical priority pathogens No No Yes NA NA WHO AMR pipeline analysis Nov-21 Durlobactam + sulbactam ETX2514 Antibiotics NA DBO-BLI /PBP2 binder + β-lactam-BLI/PBP1,3 binder A. baumannii HAP, VAP IV Phase III NCT03445195, NCT03894046 Entasis Therapeutics Inc. Priority pathogens Acinetobacter baumannii Critical priority pathogens Yes No Yes NA NA WHO AMR pipeline analysis Nov-21 EBL-1003 Apramycin Antibiotics NA Aminoglycoside Bacterial infections IV Phase I NCT04105205 Juvabis Priority pathogens Streptococcus pneumoniae Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 EBL-1003 Apramycin Antibiotics NA Aminoglycoside Bacterial infections IV Phase I NCT04105205 Juvabis Priority pathogens Staphylococcus aureus Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 EBL-1003 Apramycin Antibiotics NA Aminoglycoside Bacterial infections IV Phase I NCT04105205 Juvabis Priority pathogens Pseudomonas aeruginosa Critical priority pathogens Possibly No Yes NA NA WHO AMR pipeline analysis Nov-21 EBL-1003 Apramycin Antibiotics NA Aminoglycoside Bacterial infections IV Phase I NCT04105205 Juvabis Priority pathogens Other priority pathogens Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 EBL-1003 Apramycin Antibiotics NA Aminoglycoside Bacterial infections IV Phase I NCT04105205 Juvabis Priority pathogens Neisseria gonnorhoeae Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 EBL-1003 Apramycin Antibiotics NA Aminoglycoside Bacterial infections IV Phase I NCT04105205 Juvabis Priority pathogens Helicobacter pylori Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 EBL-1003 Apramycin Antibiotics NA Aminoglycoside Bacterial infections IV Phase I NCT04105205 Juvabis Priority pathogens Gram-positive priority pathogens Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 EBL-1003 Apramycin Antibiotics NA Aminoglycoside Bacterial infections IV Phase I NCT04105205 Juvabis Priority pathogens Enterococcus faecium Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 EBL-1003 Apramycin Antibiotics NA Aminoglycoside Bacterial infections IV Phase I NCT04105205 Juvabis Priority pathogens Enterobacterales Critical priority pathogens Yes No Yes NA NA WHO AMR pipeline analysis Nov-21 EBL-1003 Apramycin Antibiotics NA Aminoglycoside Bacterial infections IV Phase I NCT04105205 Juvabis Priority pathogens Critical priority pathogens Critical priority pathogens Yes No Yes NA NA WHO AMR pipeline analysis Nov-21 EBL-1003 Apramycin Antibiotics NA Aminoglycoside Bacterial infections IV Phase I NCT04105205 Juvabis Priority pathogens Campylobacter spp. Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 EBL-1003 Apramycin Antibiotics NA Aminoglycoside Bacterial infections IV Phase I NCT04105205 Juvabis Priority pathogens All critical priority pathogens Critical priority pathogens No No Yes NA NA WHO AMR pipeline analysis Nov-21 EBL-1003 Apramycin Antibiotics NA Aminoglycoside Bacterial infections IV Phase I NCT04105205 Juvabis Priority pathogens Acinetobacter baumannii Critical priority pathogens Yes No Yes NA NA WHO AMR pipeline analysis Nov-21 Enmetazobactam + cefepime AAl101 + cefepime Antibiotics NA β-lactam BLI + cephalosporin cUTI, AP IV Phase III EudraCT 2017-004868-35, NCT03687255 Allecra therapeutics Priority pathogens Acinetobacter baumannii Critical priority pathogens Possibly No Yes NA NA WHO AMR pipeline analysis Nov-21 Enmetazobactam + cefepime AAl101 + cefepime Antibiotics NA β-lactam BLI + cephalosporin cUTI, AP IV Phase III EudraCT 2017-004868-35, NCT03687255 Allecra therapeutics Priority pathogens Enterobacterales Critical priority pathogens Possibly No Yes NA NA WHO AMR pipeline analysis Nov-21 Enmetazobactam + cefepime AAl101 + cefepime Antibiotics NA β-lactam BLI + cephalosporin cUTI, AP IV Phase III EudraCT 2017-004868-35, NCT03687255 Allecra therapeutics Priority pathogens Pseudomonas aeruginosa Critical priority pathogens Possibly No Yes NA NA WHO AMR pipeline analysis Nov-21 Enmetazobactam + cefepime AAl101 + cefepime Antibiotics NA β-lactam BLI + cephalosporin cUTI, AP IV Phase III EudraCT 2017-004868-35, NCT03687255 Allecra therapeutics Priority pathogens Campylobacter spp. Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 Enmetazobactam + cefepime AAl101 + cefepime Antibiotics NA β-lactam BLI + cephalosporin cUTI, AP IV Phase III EudraCT 2017-004868-35, NCT03687255 Allecra therapeutics Priority pathogens Enterococcus faecium Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 Enmetazobactam + cefepime AAl101 + cefepime Antibiotics NA β-lactam BLI + cephalosporin cUTI, AP IV Phase III EudraCT 2017-004868-35, NCT03687255 Allecra therapeutics Priority pathogens Gram-positive priority pathogens Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 Enmetazobactam + cefepime AAl101 + cefepime Antibiotics NA β-lactam BLI + cephalosporin cUTI, AP IV Phase III EudraCT 2017-004868-35, NCT03687255 Allecra therapeutics Priority pathogens Helicobacter pylori Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 Enmetazobactam + cefepime AAl101 + cefepime Antibiotics NA β-lactam BLI + cephalosporin cUTI, AP IV Phase III EudraCT 2017-004868-35, NCT03687255 Allecra therapeutics Priority pathogens Neisseria gonnorhoeae Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 Enmetazobactam + cefepime AAl101 + cefepime Antibiotics NA β-lactam BLI + cephalosporin cUTI, AP IV Phase III EudraCT 2017-004868-35, NCT03687255 Allecra therapeutics Priority pathogens Other priority pathogens Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 Enmetazobactam + cefepime AAl101 + cefepime Antibiotics NA β-lactam BLI + cephalosporin cUTI, AP IV Phase III EudraCT 2017-004868-35, NCT03687255 Allecra therapeutics Priority pathogens Staphylococcus aureus Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 Enmetazobactam + cefepime AAl101 + cefepime Antibiotics NA β-lactam BLI + cephalosporin cUTI, AP IV Phase III EudraCT 2017-004868-35, NCT03687255 Allecra therapeutics Priority pathogens Streptococcus pneumoniae Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 Enmetazobactam + cefepime AAl101 + cefepime Antibiotics NA β-lactam BLI + cephalosporin cUTI, AP IV Phase III EudraCT 2017-004868-35, NCT03687255 Allecra therapeutics Priority pathogens All critical priority pathogens Critical priority pathogens No No Yes NA NA WHO AMR pipeline analysis Nov-21 Enmetazobactam + cefepime AAl101 + cefepime Antibiotics NA β-lactam BLI + cephalosporin cUTI, AP IV Phase III EudraCT 2017-004868-35, NCT03687255 Allecra therapeutics Priority pathogens Critical priority pathogens Critical priority pathogens Yes No Yes NA NA WHO AMR pipeline analysis Nov-21 ETX0282 + cefpodoxime – Antibiotics NA DBO-BLI/PBP2 binder + cephalosporin Active against ESBL, OXA-48 and KPC, but not MBL-producing Enterobacterales Oral Phase I NCT03491748 Entasis Therapeutics Inc. Priority pathogens Streptococcus pneumoniae Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 ETX0282 + cefpodoxime – Antibiotics NA DBO-BLI/PBP2 binder + cephalosporin Active against ESBL, OXA-48 and KPC, but not MBL-producing Enterobacterales Oral Phase I NCT03491748 Entasis Therapeutics Inc. Priority pathogens Staphylococcus aureus Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 ETX0282 + cefpodoxime – Antibiotics NA DBO-BLI/PBP2 binder + cephalosporin Active against ESBL, OXA-48 and KPC, but not MBL-producing Enterobacterales Oral Phase I NCT03491748 Entasis Therapeutics Inc. Priority pathogens Pseudomonas aeruginosa Critical priority pathogens Possibly No Yes NA NA WHO AMR pipeline analysis Nov-21 ETX0282 + cefpodoxime – Antibiotics NA DBO-BLI/PBP2 binder + cephalosporin Active against ESBL, OXA-48 and KPC, but not MBL-producing Enterobacterales Oral Phase I NCT03491748 Entasis Therapeutics Inc. Priority pathogens Other priority pathogens Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 ETX0282 + cefpodoxime – Antibiotics NA DBO-BLI/PBP2 binder + cephalosporin Active against ESBL, OXA-48 and KPC, but not MBL-producing Enterobacterales Oral Phase I NCT03491748 Entasis Therapeutics Inc. Priority pathogens Neisseria gonnorhoeae Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 ETX0282 + cefpodoxime – Antibiotics NA DBO-BLI/PBP2 binder + cephalosporin Active against ESBL, OXA-48 and KPC, but not MBL-producing Enterobacterales Oral Phase I NCT03491748 Entasis Therapeutics Inc. Priority pathogens Helicobacter pylori Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 ETX0282 + cefpodoxime – Antibiotics NA DBO-BLI/PBP2 binder + cephalosporin Active against ESBL, OXA-48 and KPC, but not MBL-producing Enterobacterales Oral Phase I NCT03491748 Entasis Therapeutics Inc. Priority pathogens Gram-positive priority pathogens Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 ETX0282 + cefpodoxime – Antibiotics NA DBO-BLI/PBP2 binder + cephalosporin Active against ESBL, OXA-48 and KPC, but not MBL-producing Enterobacterales Oral Phase I NCT03491748 Entasis Therapeutics Inc. Priority pathogens Enterococcus faecium Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 ETX0282 + cefpodoxime – Antibiotics NA DBO-BLI/PBP2 binder + cephalosporin Active against ESBL, OXA-48 and KPC, but not MBL-producing Enterobacterales Oral Phase I NCT03491748 Entasis Therapeutics Inc. Priority pathogens Enterobacterales Critical priority pathogens Yes No Yes NA NA WHO AMR pipeline analysis Nov-21 ETX0282 + cefpodoxime – Antibiotics NA DBO-BLI/PBP2 binder + cephalosporin Active against ESBL, OXA-48 and KPC, but not MBL-producing Enterobacterales Oral Phase I NCT03491748 Entasis Therapeutics Inc. Priority pathogens Critical priority pathogens Critical priority pathogens Yes No Yes NA NA WHO AMR pipeline analysis Nov-21 ETX0282 + cefpodoxime – Antibiotics NA DBO-BLI/PBP2 binder + cephalosporin Active against ESBL, OXA-48 and KPC, but not MBL-producing Enterobacterales Oral Phase I NCT03491748 Entasis Therapeutics Inc. Priority pathogens Campylobacter spp. Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 ETX0282 + cefpodoxime – Antibiotics NA DBO-BLI/PBP2 binder + cephalosporin Active against ESBL, OXA-48 and KPC, but not MBL-producing Enterobacterales Oral Phase I NCT03491748 Entasis Therapeutics Inc. Priority pathogens All critical priority pathogens Critical priority pathogens No No Yes NA NA WHO AMR pipeline analysis Nov-21 ETX0282 + cefpodoxime – Antibiotics NA DBO-BLI/PBP2 binder + cephalosporin Active against ESBL, OXA-48 and KPC, but not MBL-producing Enterobacterales Oral Phase I NCT03491748 Entasis Therapeutics Inc. Priority pathogens Acinetobacter baumannii Critical priority pathogens Possibly No Yes NA NA WHO AMR pipeline analysis Nov-21 Ftortiazinon + cefepime Fluorothyazinone Non-traditional Miscellaneous Type III secretion system inhibition + cefepime P. aeruginosa cUTI Oral Phase II NCT03638830 Gamaleya Research Institute of Epidemiology and Microbiology Priority pathogens Streptococcus pneumoniae Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 Ftortiazinon + cefepime Fluorothyazinone Non-traditional Miscellaneous Type III secretion system inhibition + cefepime P. aeruginosa cUTI Oral Phase II NCT03638830 Gamaleya Research Institute of Epidemiology and Microbiology Priority pathogens Staphylococcus aureus Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 Ftortiazinon + cefepime Fluorothyazinone Non-traditional Miscellaneous Type III secretion system inhibition + cefepime P. aeruginosa cUTI Oral Phase II NCT03638830 Gamaleya Research Institute of Epidemiology and Microbiology Priority pathogens Pseudomonas aeruginosa Critical priority pathogens Yes N/A Yes NA NA WHO AMR pipeline analysis Nov-21 Ftortiazinon + cefepime Fluorothyazinone Non-traditional Miscellaneous Type III secretion system inhibition + cefepime P. aeruginosa cUTI Oral Phase II NCT03638830 Gamaleya Research Institute of Epidemiology and Microbiology Priority pathogens Other priority pathogens Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 Ftortiazinon + cefepime Fluorothyazinone Non-traditional Miscellaneous Type III secretion system inhibition + cefepime P. aeruginosa cUTI Oral Phase II NCT03638830 Gamaleya Research Institute of Epidemiology and Microbiology Priority pathogens Neisseria gonnorhoeae Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 Ftortiazinon + cefepime Fluorothyazinone Non-traditional Miscellaneous Type III secretion system inhibition + cefepime P. aeruginosa cUTI Oral Phase II NCT03638830 Gamaleya Research Institute of Epidemiology and Microbiology Priority pathogens Helicobacter pylori Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 Ftortiazinon + cefepime Fluorothyazinone Non-traditional Miscellaneous Type III secretion system inhibition + cefepime P. aeruginosa cUTI Oral Phase II NCT03638830 Gamaleya Research Institute of Epidemiology and Microbiology Priority pathogens Gram-positive priority pathogens Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 Ftortiazinon + cefepime Fluorothyazinone Non-traditional Miscellaneous Type III secretion system inhibition + cefepime P. aeruginosa cUTI Oral Phase II NCT03638830 Gamaleya Research Institute of Epidemiology and Microbiology Priority pathogens Enterococcus faecium Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 Ftortiazinon + cefepime Fluorothyazinone Non-traditional Miscellaneous Type III secretion system inhibition + cefepime P. aeruginosa cUTI Oral Phase II NCT03638830 Gamaleya Research Institute of Epidemiology and Microbiology Priority pathogens Enterobacterales Critical priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 Ftortiazinon + cefepime Fluorothyazinone Non-traditional Miscellaneous Type III secretion system inhibition + cefepime P. aeruginosa cUTI Oral Phase II NCT03638830 Gamaleya Research Institute of Epidemiology and Microbiology Priority pathogens Critical priority pathogens Critical priority pathogens Yes N/A Yes NA NA WHO AMR pipeline analysis Nov-21 Ftortiazinon + cefepime Fluorothyazinone Non-traditional Miscellaneous Type III secretion system inhibition + cefepime P. aeruginosa cUTI Oral Phase II NCT03638830 Gamaleya Research Institute of Epidemiology and Microbiology Priority pathogens Campylobacter spp. Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 Ftortiazinon + cefepime Fluorothyazinone Non-traditional Miscellaneous Type III secretion system inhibition + cefepime P. aeruginosa cUTI Oral Phase II NCT03638830 Gamaleya Research Institute of Epidemiology and Microbiology Priority pathogens All critical priority pathogens Critical priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 Ftortiazinon + cefepime Fluorothyazinone Non-traditional Miscellaneous Type III secretion system inhibition + cefepime P. aeruginosa cUTI Oral Phase II NCT03638830 Gamaleya Research Institute of Epidemiology and Microbiology Priority pathogens Acinetobacter baumannii Critical priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 Gepotidacin GSK2140944 Antibiotics NA Topoisomerase Inhibitors (Triazaacenaphthylene) Uncomplicated urogenital gonorrhea and uUTI IV, Oral Phase III NCT04010539, NCT04020341 GSK Priority pathogens Acinetobacter baumannii Critical priority pathogens N/A Yes Yes NA NA WHO AMR pipeline analysis Nov-21 Gepotidacin GSK2140944 Antibiotics NA Topoisomerase Inhibitors (Triazaacenaphthylene) Uncomplicated urogenital gonorrhea and uUTI IV, Oral Phase III NCT04010539, NCT04020341 GSK Priority pathogens All critical priority pathogens Critical priority pathogens N/A Yes Yes NA NA WHO AMR pipeline analysis Nov-21 Gepotidacin GSK2140944 Antibiotics NA Topoisomerase Inhibitors (Triazaacenaphthylene) Uncomplicated urogenital gonorrhea and uUTI IV, Oral Phase III NCT04010539, NCT04020341 GSK Priority pathogens Critical priority pathogens Critical priority pathogens N/A Yes Yes NA NA WHO AMR pipeline analysis Nov-21 Gepotidacin GSK2140944 Antibiotics NA Topoisomerase Inhibitors (Triazaacenaphthylene) Uncomplicated urogenital gonorrhea and uUTI IV, Oral Phase III NCT04010539, NCT04020341 GSK Priority pathogens Enterobacterales Critical priority pathogens N/A Yes Yes NA NA WHO AMR pipeline analysis Nov-21 Gepotidacin GSK2140944 Antibiotics NA Topoisomerase Inhibitors (Triazaacenaphthylene) Uncomplicated urogenital gonorrhea and uUTI IV, Oral Phase III NCT04010539, NCT04020341 GSK Priority pathogens Campylobacter spp. Other priority pathogens No Yes Yes NA NA WHO AMR pipeline analysis Nov-21 Gepotidacin GSK2140944 Antibiotics NA Topoisomerase Inhibitors (Triazaacenaphthylene) Uncomplicated urogenital gonorrhea and uUTI IV, Oral Phase III NCT04010539, NCT04020341 GSK Priority pathogens Enterococcus faecium Other priority pathogens No Yes Yes NA NA WHO AMR pipeline analysis Nov-21 Gepotidacin GSK2140944 Antibiotics NA Topoisomerase Inhibitors (Triazaacenaphthylene) Uncomplicated urogenital gonorrhea and uUTI IV, Oral Phase III NCT04010539, NCT04020341 GSK Priority pathogens Helicobacter pylori Other priority pathogens No Yes Yes NA NA WHO AMR pipeline analysis Nov-21 Gepotidacin GSK2140944 Antibiotics NA Topoisomerase Inhibitors (Triazaacenaphthylene) Uncomplicated urogenital gonorrhea and uUTI IV, Oral Phase III NCT04010539, NCT04020341 GSK Priority pathogens Pseudomonas aeruginosa Critical priority pathogens No Yes Yes NA NA WHO AMR pipeline analysis Nov-21 Gepotidacin GSK2140944 Antibiotics NA Topoisomerase Inhibitors (Triazaacenaphthylene) Uncomplicated urogenital gonorrhea and uUTI IV, Oral Phase III NCT04010539, NCT04020341 GSK Priority pathogens Streptococcus pneumoniae Other priority pathogens No Yes Yes NA NA WHO AMR pipeline analysis Nov-21 Gepotidacin GSK2140944 Antibiotics NA Topoisomerase Inhibitors (Triazaacenaphthylene) Uncomplicated urogenital gonorrhea and uUTI IV, Oral Phase III NCT04010539, NCT04020341 GSK Priority pathogens Gram-positive priority pathogens Other priority pathogens Yes Yes Yes NA NA WHO AMR pipeline analysis Nov-21 Gepotidacin GSK2140944 Antibiotics NA Topoisomerase Inhibitors (Triazaacenaphthylene) Uncomplicated urogenital gonorrhea and uUTI IV, Oral Phase III NCT04010539, NCT04020341 GSK Priority pathogens Neisseria gonnorhoeae Other priority pathogens Yes Yes Yes NA NA WHO AMR pipeline analysis Nov-21 Gepotidacin GSK2140944 Antibiotics NA Topoisomerase Inhibitors (Triazaacenaphthylene) Uncomplicated urogenital gonorrhea and uUTI IV, Oral Phase III NCT04010539, NCT04020341 GSK Priority pathogens Other priority pathogens Other priority pathogens Yes Yes Yes NA NA WHO AMR pipeline analysis Nov-21 Gepotidacin GSK2140944 Antibiotics NA Topoisomerase Inhibitors (Triazaacenaphthylene) Uncomplicated urogenital gonorrhea and uUTI IV, Oral Phase III NCT04010539, NCT04020341 GSK Priority pathogens Staphylococcus aureus Other priority pathogens Yes Yes Yes NA NA WHO AMR pipeline analysis Nov-21 GSK3882347 - Non-traditional Miscellaneous Undisclosed (FimH) E.coli UTI Oral Phase I NCT04488770 GSK Priority pathogens Streptococcus pneumoniae Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 GSK3882347 - Non-traditional Miscellaneous Undisclosed (FimH) E.coli UTI Oral Phase I NCT04488770 GSK Priority pathogens Staphylococcus aureus Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 GSK3882347 - Non-traditional Miscellaneous Undisclosed (FimH) E.coli UTI Oral Phase I NCT04488770 GSK Priority pathogens Pseudomonas aeruginosa Critical priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 GSK3882347 - Non-traditional Miscellaneous Undisclosed (FimH) E.coli UTI Oral Phase I NCT04488770 GSK Priority pathogens Other priority pathogens Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 GSK3882347 - Non-traditional Miscellaneous Undisclosed (FimH) E.coli UTI Oral Phase I NCT04488770 GSK Priority pathogens Neisseria gonnorhoeae Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 GSK3882347 - Non-traditional Miscellaneous Undisclosed (FimH) E.coli UTI Oral Phase I NCT04488770 GSK Priority pathogens Helicobacter pylori Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 GSK3882347 - Non-traditional Miscellaneous Undisclosed (FimH) E.coli UTI Oral Phase I NCT04488770 GSK Priority pathogens Gram-positive priority pathogens Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 GSK3882347 - Non-traditional Miscellaneous Undisclosed (FimH) E.coli UTI Oral Phase I NCT04488770 GSK Priority pathogens Enterococcus faecium Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 GSK3882347 - Non-traditional Miscellaneous Undisclosed (FimH) E.coli UTI Oral Phase I NCT04488770 GSK Priority pathogens Enterobacterales Critical priority pathogens Yes N/A Yes NA NA WHO AMR pipeline analysis Nov-21 GSK3882347 - Non-traditional Miscellaneous Undisclosed (FimH) E.coli UTI Oral Phase I NCT04488770 GSK Priority pathogens Critical priority pathogens Critical priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 GSK3882347 - Non-traditional Miscellaneous Undisclosed (FimH) E.coli UTI Oral Phase I NCT04488770 GSK Priority pathogens Campylobacter spp. Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 GSK3882347 - Non-traditional Miscellaneous Undisclosed (FimH) E.coli UTI Oral Phase I NCT04488770 GSK Priority pathogens All critical priority pathogens Critical priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 GSK3882347 - Non-traditional Miscellaneous Undisclosed (FimH) E.coli UTI Oral Phase I NCT04488770 GSK Priority pathogens Acinetobacter baumannii Critical priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 KBP-7072 – Antibiotics NA Tetracycline Multi-drug resistant bacterial infections including (CABP, DFI, cUTI, cIAI) Oral Phase I NCT02454361, NCT02654626, NCT04532957 KBP BioSciences Pharmaceutical Technical Co., Ltd. Priority pathogens Streptococcus pneumoniae Other priority pathogens No No Yes NA NA WHO AMR pipeline analysis Nov-21 KBP-7072 – Antibiotics NA Tetracycline Multi-drug resistant bacterial infections including (CABP, DFI, cUTI, cIAI) Oral Phase I NCT02454361, NCT02654626, NCT04532957 KBP BioSciences Pharmaceutical Technical Co., Ltd. Priority pathogens Staphylococcus aureus Other priority pathogens Yes No Yes NA NA WHO AMR pipeline analysis Nov-21 KBP-7072 – Antibiotics NA Tetracycline Multi-drug resistant bacterial infections including (CABP, DFI, cUTI, cIAI) Oral Phase I NCT02454361, NCT02654626, NCT04532957 KBP BioSciences Pharmaceutical Technical Co., Ltd. Priority pathogens Pseudomonas aeruginosa Critical priority pathogens Possibly No Yes NA NA WHO AMR pipeline analysis Nov-21 KBP-7072 – Antibiotics NA Tetracycline Multi-drug resistant bacterial infections including (CABP, DFI, cUTI, cIAI) Oral Phase I NCT02454361, NCT02654626, NCT04532957 KBP BioSciences Pharmaceutical Technical Co., Ltd. Priority pathogens Other priority pathogens Other priority pathogens Yes No Yes NA NA WHO AMR pipeline analysis Nov-21 KBP-7072 – Antibiotics NA Tetracycline Multi-drug resistant bacterial infections including (CABP, DFI, cUTI, cIAI) Oral Phase I NCT02454361, NCT02654626, NCT04532957 KBP BioSciences Pharmaceutical Technical Co., Ltd. Priority pathogens Neisseria gonnorhoeae Other priority pathogens No No Yes NA NA WHO AMR pipeline analysis Nov-21 KBP-7072 – Antibiotics NA Tetracycline Multi-drug resistant bacterial infections including (CABP, DFI, cUTI, cIAI) Oral Phase I NCT02454361, NCT02654626, NCT04532957 KBP BioSciences Pharmaceutical Technical Co., Ltd. Priority pathogens Helicobacter pylori Other priority pathogens No No Yes NA NA WHO AMR pipeline analysis Nov-21 KBP-7072 – Antibiotics NA Tetracycline Multi-drug resistant bacterial infections including (CABP, DFI, cUTI, cIAI) Oral Phase I NCT02454361, NCT02654626, NCT04532957 KBP BioSciences Pharmaceutical Technical Co., Ltd. Priority pathogens Gram-positive priority pathogens Other priority pathogens Yes No Yes NA NA WHO AMR pipeline analysis Nov-21 KBP-7072 – Antibiotics NA Tetracycline Multi-drug resistant bacterial infections including (CABP, DFI, cUTI, cIAI) Oral Phase I NCT02454361, NCT02654626, NCT04532957 KBP BioSciences Pharmaceutical Technical Co., Ltd. Priority pathogens Enterococcus faecium Other priority pathogens No No Yes NA NA WHO AMR pipeline analysis Nov-21 KBP-7072 – Antibiotics NA Tetracycline Multi-drug resistant bacterial infections including (CABP, DFI, cUTI, cIAI) Oral Phase I NCT02454361, NCT02654626, NCT04532957 KBP BioSciences Pharmaceutical Technical Co., Ltd. Priority pathogens Enterobacterales Critical priority pathogens Possibly No Yes NA NA WHO AMR pipeline analysis Nov-21 KBP-7072 – Antibiotics NA Tetracycline Multi-drug resistant bacterial infections including (CABP, DFI, cUTI, cIAI) Oral Phase I NCT02454361, NCT02654626, NCT04532957 KBP BioSciences Pharmaceutical Technical Co., Ltd. Priority pathogens Critical priority pathogens Critical priority pathogens Yes No Yes NA NA WHO AMR pipeline analysis Nov-21 KBP-7072 – Antibiotics NA Tetracycline Multi-drug resistant bacterial infections including (CABP, DFI, cUTI, cIAI) Oral Phase I NCT02454361, NCT02654626, NCT04532957 KBP BioSciences Pharmaceutical Technical Co., Ltd. Priority pathogens Campylobacter spp. Other priority pathogens No No Yes NA NA WHO AMR pipeline analysis Nov-21 KBP-7072 – Antibiotics NA Tetracycline Multi-drug resistant bacterial infections including (CABP, DFI, cUTI, cIAI) Oral Phase I NCT02454361, NCT02654626, NCT04532957 KBP BioSciences Pharmaceutical Technical Co., Ltd. Priority pathogens All critical priority pathogens Critical priority pathogens No No Yes NA NA WHO AMR pipeline analysis Nov-21 KBP-7072 – Antibiotics NA Tetracycline Multi-drug resistant bacterial infections including (CABP, DFI, cUTI, cIAI) Oral Phase I NCT02454361, NCT02654626, NCT04532957 KBP BioSciences Pharmaceutical Technical Co., Ltd. Priority pathogens Acinetobacter baumannii Critical priority pathogens Yes No Yes NA NA WHO AMR pipeline analysis Nov-21 LBP-EC01 – Non-traditional Bacteriophages and phage-derived enzymes CRISPR-Cas3 enhanced phage E. coli IV Phase I NCT04191148 Locus Bioscience Priority pathogens Streptococcus pneumoniae Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 LBP-EC01 – Non-traditional Bacteriophages and phage-derived enzymes CRISPR-Cas3 enhanced phage E. coli IV Phase I NCT04191148 Locus Bioscience Priority pathogens Staphylococcus aureus Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 LBP-EC01 – Non-traditional Bacteriophages and phage-derived enzymes CRISPR-Cas3 enhanced phage E. coli IV Phase I NCT04191148 Locus Bioscience Priority pathogens Pseudomonas aeruginosa Critical priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 LBP-EC01 – Non-traditional Bacteriophages and phage-derived enzymes CRISPR-Cas3 enhanced phage E. coli IV Phase I NCT04191148 Locus Bioscience Priority pathogens Other priority pathogens Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 LBP-EC01 – Non-traditional Bacteriophages and phage-derived enzymes CRISPR-Cas3 enhanced phage E. coli IV Phase I NCT04191148 Locus Bioscience Priority pathogens Neisseria gonnorhoeae Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 LBP-EC01 – Non-traditional Bacteriophages and phage-derived enzymes CRISPR-Cas3 enhanced phage E. coli IV Phase I NCT04191148 Locus Bioscience Priority pathogens Helicobacter pylori Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 LBP-EC01 – Non-traditional Bacteriophages and phage-derived enzymes CRISPR-Cas3 enhanced phage E. coli IV Phase I NCT04191148 Locus Bioscience Priority pathogens Gram-positive priority pathogens Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 LBP-EC01 – Non-traditional Bacteriophages and phage-derived enzymes CRISPR-Cas3 enhanced phage E. coli IV Phase I NCT04191148 Locus Bioscience Priority pathogens Enterococcus faecium Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 LBP-EC01 – Non-traditional Bacteriophages and phage-derived enzymes CRISPR-Cas3 enhanced phage E. coli IV Phase I NCT04191148 Locus Bioscience Priority pathogens Enterobacterales Critical priority pathogens Yes N/A Yes NA NA WHO AMR pipeline analysis Nov-21 LBP-EC01 – Non-traditional Bacteriophages and phage-derived enzymes CRISPR-Cas3 enhanced phage E. coli IV Phase I NCT04191148 Locus Bioscience Priority pathogens Critical priority pathogens Critical priority pathogens Yes N/A Yes NA NA WHO AMR pipeline analysis Nov-21 LBP-EC01 – Non-traditional Bacteriophages and phage-derived enzymes CRISPR-Cas3 enhanced phage E. coli IV Phase I NCT04191148 Locus Bioscience Priority pathogens Campylobacter spp. Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 LBP-EC01 – Non-traditional Bacteriophages and phage-derived enzymes CRISPR-Cas3 enhanced phage E. coli IV Phase I NCT04191148 Locus Bioscience Priority pathogens All critical priority pathogens Critical priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 LBP-EC01 – Non-traditional Bacteriophages and phage-derived enzymes CRISPR-Cas3 enhanced phage E. coli IV Phase I NCT04191148 Locus Bioscience Priority pathogens Acinetobacter baumannii Critical priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 LMN-101 – Non-traditional Antibodies "Monoclonal Ab like recombinant protein" E. coli and C. jejuni infections Oral Phase II NCT04098263, NCT04182490 Lumen Bioscience Priority pathogens Streptococcus pneumoniae Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 LMN-101 – Non-traditional Antibodies "Monoclonal Ab like recombinant protein" E. coli and C. jejuni infections Oral Phase II NCT04098263, NCT04182490 Lumen Bioscience Priority pathogens Staphylococcus aureus Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 LMN-101 – Non-traditional Antibodies "Monoclonal Ab like recombinant protein" E. coli and C. jejuni infections Oral Phase II NCT04098263, NCT04182490 Lumen Bioscience Priority pathogens Pseudomonas aeruginosa Critical priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 LMN-101 – Non-traditional Antibodies "Monoclonal Ab like recombinant protein" E. coli and C. jejuni infections Oral Phase II NCT04098263, NCT04182490 Lumen Bioscience Priority pathogens Other priority pathogens Other priority pathogens Yes N/A Yes NA NA WHO AMR pipeline analysis Nov-21 LMN-101 – Non-traditional Antibodies "Monoclonal Ab like recombinant protein" E. coli and C. jejuni infections Oral Phase II NCT04098263, NCT04182490 Lumen Bioscience Priority pathogens Neisseria gonnorhoeae Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 LMN-101 – Non-traditional Antibodies "Monoclonal Ab like recombinant protein" E. coli and C. jejuni infections Oral Phase II NCT04098263, NCT04182490 Lumen Bioscience Priority pathogens Helicobacter pylori Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 LMN-101 – Non-traditional Antibodies "Monoclonal Ab like recombinant protein" E. coli and C. jejuni infections Oral Phase II NCT04098263, NCT04182490 Lumen Bioscience Priority pathogens Gram-positive priority pathogens Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 LMN-101 – Non-traditional Antibodies "Monoclonal Ab like recombinant protein" E. coli and C. jejuni infections Oral Phase II NCT04098263, NCT04182490 Lumen Bioscience Priority pathogens Enterococcus faecium Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 LMN-101 – Non-traditional Antibodies "Monoclonal Ab like recombinant protein" E. coli and C. jejuni infections Oral Phase II NCT04098263, NCT04182490 Lumen Bioscience Priority pathogens Enterobacterales Critical priority pathogens Yes N/A Yes NA NA WHO AMR pipeline analysis Nov-21 LMN-101 – Non-traditional Antibodies "Monoclonal Ab like recombinant protein" E. coli and C. jejuni infections Oral Phase II NCT04098263, NCT04182490 Lumen Bioscience Priority pathogens Critical priority pathogens Critical priority pathogens Yes N/A Yes NA NA WHO AMR pipeline analysis Nov-21 LMN-101 – Non-traditional Antibodies "Monoclonal Ab like recombinant protein" E. coli and C. jejuni infections Oral Phase II NCT04098263, NCT04182490 Lumen Bioscience Priority pathogens Campylobacter spp. Other priority pathogens Yes N/A Yes NA NA WHO AMR pipeline analysis Nov-21 LMN-101 – Non-traditional Antibodies "Monoclonal Ab like recombinant protein" E. coli and C. jejuni infections Oral Phase II NCT04098263, NCT04182490 Lumen Bioscience Priority pathogens All critical priority pathogens Critical priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 LMN-101 – Non-traditional Antibodies "Monoclonal Ab like recombinant protein" E. coli and C. jejuni infections Oral Phase II NCT04098263, NCT04182490 Lumen Bioscience Priority pathogens Acinetobacter baumannii Critical priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 LSVT-1701 Tonabacase, SAL200 Non-traditional Bacteriophages and phage-derived enzymes Phage endolysin S. aureus bacteremia IV Phase II NCT03089697, NCT03446053 Roivant Sciences/iNtRON Biotechnology Priority pathogens Streptococcus pneumoniae Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 LSVT-1701 Tonabacase, SAL200 Non-traditional Bacteriophages and phage-derived enzymes Phage endolysin S. aureus bacteremia IV Phase II NCT03089697, NCT03446053 Roivant Sciences/iNtRON Biotechnology Priority pathogens Staphylococcus aureus Other priority pathogens Yes N/A Yes NA NA WHO AMR pipeline analysis Nov-21 LSVT-1701 Tonabacase, SAL200 Non-traditional Bacteriophages and phage-derived enzymes Phage endolysin S. aureus bacteremia IV Phase II NCT03089697, NCT03446053 Roivant Sciences/iNtRON Biotechnology Priority pathogens Pseudomonas aeruginosa Critical priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 LSVT-1701 Tonabacase, SAL200 Non-traditional Bacteriophages and phage-derived enzymes Phage endolysin S. aureus bacteremia IV Phase II NCT03089697, NCT03446053 Roivant Sciences/iNtRON Biotechnology Priority pathogens Other priority pathogens Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 LSVT-1701 Tonabacase, SAL200 Non-traditional Bacteriophages and phage-derived enzymes Phage endolysin S. aureus bacteremia IV Phase II NCT03089697, NCT03446053 Roivant Sciences/iNtRON Biotechnology Priority pathogens Neisseria gonnorhoeae Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 LSVT-1701 Tonabacase, SAL200 Non-traditional Bacteriophages and phage-derived enzymes Phage endolysin S. aureus bacteremia IV Phase II NCT03089697, NCT03446053 Roivant Sciences/iNtRON Biotechnology Priority pathogens Helicobacter pylori Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 LSVT-1701 Tonabacase, SAL200 Non-traditional Bacteriophages and phage-derived enzymes Phage endolysin S. aureus bacteremia IV Phase II NCT03089697, NCT03446053 Roivant Sciences/iNtRON Biotechnology Priority pathogens Gram-positive priority pathogens Other priority pathogens Yes N/A Yes NA NA WHO AMR pipeline analysis Nov-21 LSVT-1701 Tonabacase, SAL200 Non-traditional Bacteriophages and phage-derived enzymes Phage endolysin S. aureus bacteremia IV Phase II NCT03089697, NCT03446053 Roivant Sciences/iNtRON Biotechnology Priority pathogens Enterococcus faecium Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 LSVT-1701 Tonabacase, SAL200 Non-traditional Bacteriophages and phage-derived enzymes Phage endolysin S. aureus bacteremia IV Phase II NCT03089697, NCT03446053 Roivant Sciences/iNtRON Biotechnology Priority pathogens Enterobacterales Critical priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 LSVT-1701 Tonabacase, SAL200 Non-traditional Bacteriophages and phage-derived enzymes Phage endolysin S. aureus bacteremia IV Phase II NCT03089697, NCT03446053 Roivant Sciences/iNtRON Biotechnology Priority pathogens Critical priority pathogens Critical priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 LSVT-1701 Tonabacase, SAL200 Non-traditional Bacteriophages and phage-derived enzymes Phage endolysin S. aureus bacteremia IV Phase II NCT03089697, NCT03446053 Roivant Sciences/iNtRON Biotechnology Priority pathogens Campylobacter spp. Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 LSVT-1701 Tonabacase, SAL200 Non-traditional Bacteriophages and phage-derived enzymes Phage endolysin S. aureus bacteremia IV Phase II NCT03089697, NCT03446053 Roivant Sciences/iNtRON Biotechnology Priority pathogens All critical priority pathogens Critical priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 LSVT-1701 Tonabacase, SAL200 Non-traditional Bacteriophages and phage-derived enzymes Phage endolysin S. aureus bacteremia IV Phase II NCT03089697, NCT03446053 Roivant Sciences/iNtRON Biotechnology Priority pathogens Acinetobacter baumannii Critical priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 MRX-8 - Antibiotics NA Polymyxin Gram-negative infections IV Phase I NCT04649541 MicuRx Priority pathogens Streptococcus pneumoniae Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 MRX-8 - Antibiotics NA Polymyxin Gram-negative infections IV Phase I NCT04649541 MicuRx Priority pathogens Staphylococcus aureus Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 MRX-8 - Antibiotics NA Polymyxin Gram-negative infections IV Phase I NCT04649541 MicuRx Priority pathogens Pseudomonas aeruginosa Critical priority pathogens Yes No Yes NA NA WHO AMR pipeline analysis Nov-21 MRX-8 - Antibiotics NA Polymyxin Gram-negative infections IV Phase I NCT04649541 MicuRx Priority pathogens Other priority pathogens Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 MRX-8 - Antibiotics NA Polymyxin Gram-negative infections IV Phase I NCT04649541 MicuRx Priority pathogens Neisseria gonnorhoeae Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 MRX-8 - Antibiotics NA Polymyxin Gram-negative infections IV Phase I NCT04649541 MicuRx Priority pathogens Helicobacter pylori Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 MRX-8 - Antibiotics NA Polymyxin Gram-negative infections IV Phase I NCT04649541 MicuRx Priority pathogens Gram-positive priority pathogens Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 MRX-8 - Antibiotics NA Polymyxin Gram-negative infections IV Phase I NCT04649541 MicuRx Priority pathogens Enterococcus faecium Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 MRX-8 - Antibiotics NA Polymyxin Gram-negative infections IV Phase I NCT04649541 MicuRx Priority pathogens Enterobacterales Critical priority pathogens Yes No Yes NA NA WHO AMR pipeline analysis Nov-21 MRX-8 - Antibiotics NA Polymyxin Gram-negative infections IV Phase I NCT04649541 MicuRx Priority pathogens Critical priority pathogens Critical priority pathogens Yes No Yes NA NA WHO AMR pipeline analysis Nov-21 MRX-8 - Antibiotics NA Polymyxin Gram-negative infections IV Phase I NCT04649541 MicuRx Priority pathogens Campylobacter spp. Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 MRX-8 - Antibiotics NA Polymyxin Gram-negative infections IV Phase I NCT04649541 MicuRx Priority pathogens All critical priority pathogens Critical priority pathogens Yes No Yes NA NA WHO AMR pipeline analysis Nov-21 MRX-8 - Antibiotics NA Polymyxin Gram-negative infections IV Phase I NCT04649541 MicuRx Priority pathogens Acinetobacter baumannii Critical priority pathogens Yes No Yes NA NA WHO AMR pipeline analysis Nov-21 Nacubactam + meropenem OP0595 Antibiotics NA DBO-BLI/PBP2 binder + cephalosporin Bacterial infections IV Phase I NCT03174795 Meiji Seika Priority pathogens Streptococcus pneumoniae Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 Nacubactam + meropenem OP0595 Antibiotics NA DBO-BLI/PBP2 binder + cephalosporin Bacterial infections IV Phase I NCT03174795 Meiji Seika Priority pathogens Staphylococcus aureus Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 Nacubactam + meropenem OP0595 Antibiotics NA DBO-BLI/PBP2 binder + cephalosporin Bacterial infections IV Phase I NCT03174795 Meiji Seika Priority pathogens Pseudomonas aeruginosa Critical priority pathogens Possibly No Yes NA NA WHO AMR pipeline analysis Nov-21 Nacubactam + meropenem OP0595 Antibiotics NA DBO-BLI/PBP2 binder + cephalosporin Bacterial infections IV Phase I NCT03174795 Meiji Seika Priority pathogens Other priority pathogens Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 Nacubactam + meropenem OP0595 Antibiotics NA DBO-BLI/PBP2 binder + cephalosporin Bacterial infections IV Phase I NCT03174795 Meiji Seika Priority pathogens Neisseria gonnorhoeae Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 Nacubactam + meropenem OP0595 Antibiotics NA DBO-BLI/PBP2 binder + cephalosporin Bacterial infections IV Phase I NCT03174795 Meiji Seika Priority pathogens Helicobacter pylori Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 Nacubactam + meropenem OP0595 Antibiotics NA DBO-BLI/PBP2 binder + cephalosporin Bacterial infections IV Phase I NCT03174795 Meiji Seika Priority pathogens Gram-positive priority pathogens Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 Nacubactam + meropenem OP0595 Antibiotics NA DBO-BLI/PBP2 binder + cephalosporin Bacterial infections IV Phase I NCT03174795 Meiji Seika Priority pathogens Enterococcus faecium Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 Nacubactam + meropenem OP0595 Antibiotics NA DBO-BLI/PBP2 binder + cephalosporin Bacterial infections IV Phase I NCT03174795 Meiji Seika Priority pathogens Enterobacterales Critical priority pathogens Yes No Yes NA NA WHO AMR pipeline analysis Nov-21 Nacubactam + meropenem OP0595 Antibiotics NA DBO-BLI/PBP2 binder + cephalosporin Bacterial infections IV Phase I NCT03174795 Meiji Seika Priority pathogens Critical priority pathogens Critical priority pathogens Yes No Yes NA NA WHO AMR pipeline analysis Nov-21 Nacubactam + meropenem OP0595 Antibiotics NA DBO-BLI/PBP2 binder + cephalosporin Bacterial infections IV Phase I NCT03174795 Meiji Seika Priority pathogens Campylobacter spp. Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 Nacubactam + meropenem OP0595 Antibiotics NA DBO-BLI/PBP2 binder + cephalosporin Bacterial infections IV Phase I NCT03174795 Meiji Seika Priority pathogens All critical priority pathogens Critical priority pathogens No No Yes NA NA WHO AMR pipeline analysis Nov-21 Nacubactam + meropenem OP0595 Antibiotics NA DBO-BLI/PBP2 binder + cephalosporin Bacterial infections IV Phase I NCT03174795 Meiji Seika Priority pathogens Acinetobacter baumannii Critical priority pathogens Possibly No Yes NA NA WHO AMR pipeline analysis Nov-21 Nafithromycin WCK 4873 Antibiotics NA Macrolide CABP (caused by S. pneumoniae and S. aureus) Oral Phase III NCT02903836, CTRI/2019/11/021964 Wockhardt Ltd. Priority pathogens Acinetobacter baumannii Critical priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 Nafithromycin WCK 4873 Antibiotics NA Macrolide CABP (caused by S. pneumoniae and S. aureus) Oral Phase III NCT02903836, CTRI/2019/11/021964 Wockhardt Ltd. Priority pathogens All critical priority pathogens Critical priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 Nafithromycin WCK 4873 Antibiotics NA Macrolide CABP (caused by S. pneumoniae and S. aureus) Oral Phase III NCT02903836, CTRI/2019/11/021964 Wockhardt Ltd. Priority pathogens Critical priority pathogens Critical priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 Nafithromycin WCK 4873 Antibiotics NA Macrolide CABP (caused by S. pneumoniae and S. aureus) Oral Phase III NCT02903836, CTRI/2019/11/021964 Wockhardt Ltd. Priority pathogens Enterobacterales Critical priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 Nafithromycin WCK 4873 Antibiotics NA Macrolide CABP (caused by S. pneumoniae and S. aureus) Oral Phase III NCT02903836, CTRI/2019/11/021964 Wockhardt Ltd. Priority pathogens Pseudomonas aeruginosa Critical priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 Nafithromycin WCK 4873 Antibiotics NA Macrolide CABP (caused by S. pneumoniae and S. aureus) Oral Phase III NCT02903836, CTRI/2019/11/021964 Wockhardt Ltd. Priority pathogens Campylobacter spp. Other priority pathogens No No Yes NA NA WHO AMR pipeline analysis Nov-21 Nafithromycin WCK 4873 Antibiotics NA Macrolide CABP (caused by S. pneumoniae and S. aureus) Oral Phase III NCT02903836, CTRI/2019/11/021964 Wockhardt Ltd. Priority pathogens Enterococcus faecium Other priority pathogens No No Yes NA NA WHO AMR pipeline analysis Nov-21 Nafithromycin WCK 4873 Antibiotics NA Macrolide CABP (caused by S. pneumoniae and S. aureus) Oral Phase III NCT02903836, CTRI/2019/11/021964 Wockhardt Ltd. Priority pathogens Helicobacter pylori Other priority pathogens No No Yes NA NA WHO AMR pipeline analysis Nov-21 Nafithromycin WCK 4873 Antibiotics NA Macrolide CABP (caused by S. pneumoniae and S. aureus) Oral Phase III NCT02903836, CTRI/2019/11/021964 Wockhardt Ltd. Priority pathogens Neisseria gonnorhoeae Other priority pathogens No No Yes NA NA WHO AMR pipeline analysis Nov-21 Nafithromycin WCK 4873 Antibiotics NA Macrolide CABP (caused by S. pneumoniae and S. aureus) Oral Phase III NCT02903836, CTRI/2019/11/021964 Wockhardt Ltd. Priority pathogens Gram-positive priority pathogens Other priority pathogens Yes No Yes NA NA WHO AMR pipeline analysis Nov-21 Nafithromycin WCK 4873 Antibiotics NA Macrolide CABP (caused by S. pneumoniae and S. aureus) Oral Phase III NCT02903836, CTRI/2019/11/021964 Wockhardt Ltd. Priority pathogens Other priority pathogens Other priority pathogens Yes No Yes NA NA WHO AMR pipeline analysis Nov-21 Nafithromycin WCK 4873 Antibiotics NA Macrolide CABP (caused by S. pneumoniae and S. aureus) Oral Phase III NCT02903836, CTRI/2019/11/021964 Wockhardt Ltd. Priority pathogens Staphylococcus aureus Other priority pathogens Yes No Yes NA NA WHO AMR pipeline analysis Nov-21 Nafithromycin WCK 4873 Antibiotics NA Macrolide CABP (caused by S. pneumoniae and S. aureus) Oral Phase III NCT02903836, CTRI/2019/11/021964 Wockhardt Ltd. Priority pathogens Streptococcus pneumoniae Other priority pathogens Yes No Yes NA NA WHO AMR pipeline analysis Nov-21 OligoG CF-5/20 Non-traditional Miscellaneous Alginate oligosaccharide (G-block) fragment Cystic fibrosis Inhalation Phase II NCT03822455 AlgiPharma AS Priority pathogens Streptococcus pneumoniae Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 OligoG CF-5/20 Non-traditional Miscellaneous Alginate oligosaccharide (G-block) fragment Cystic fibrosis Inhalation Phase II NCT03822455 AlgiPharma AS Priority pathogens Staphylococcus aureus Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 OligoG CF-5/20 Non-traditional Miscellaneous Alginate oligosaccharide (G-block) fragment Cystic fibrosis Inhalation Phase II NCT03822455 AlgiPharma AS Priority pathogens Pseudomonas aeruginosa Critical priority pathogens Yes N/A Yes NA NA WHO AMR pipeline analysis Nov-21 OligoG CF-5/20 Non-traditional Miscellaneous Alginate oligosaccharide (G-block) fragment Cystic fibrosis Inhalation Phase II NCT03822455 AlgiPharma AS Priority pathogens Other priority pathogens Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 OligoG CF-5/20 Non-traditional Miscellaneous Alginate oligosaccharide (G-block) fragment Cystic fibrosis Inhalation Phase II NCT03822455 AlgiPharma AS Priority pathogens Neisseria gonnorhoeae Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 OligoG CF-5/20 Non-traditional Miscellaneous Alginate oligosaccharide (G-block) fragment Cystic fibrosis Inhalation Phase II NCT03822455 AlgiPharma AS Priority pathogens Helicobacter pylori Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 OligoG CF-5/20 Non-traditional Miscellaneous Alginate oligosaccharide (G-block) fragment Cystic fibrosis Inhalation Phase II NCT03822455 AlgiPharma AS Priority pathogens Gram-positive priority pathogens Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 OligoG CF-5/20 Non-traditional Miscellaneous Alginate oligosaccharide (G-block) fragment Cystic fibrosis Inhalation Phase II NCT03822455 AlgiPharma AS Priority pathogens Enterococcus faecium Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 OligoG CF-5/20 Non-traditional Miscellaneous Alginate oligosaccharide (G-block) fragment Cystic fibrosis Inhalation Phase II NCT03822455 AlgiPharma AS Priority pathogens Enterobacterales Critical priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 OligoG CF-5/20 Non-traditional Miscellaneous Alginate oligosaccharide (G-block) fragment Cystic fibrosis Inhalation Phase II NCT03822455 AlgiPharma AS Priority pathogens Critical priority pathogens Critical priority pathogens Yes N/A Yes NA NA WHO AMR pipeline analysis Nov-21 OligoG CF-5/20 Non-traditional Miscellaneous Alginate oligosaccharide (G-block) fragment Cystic fibrosis Inhalation Phase II NCT03822455 AlgiPharma AS Priority pathogens Campylobacter spp. Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 OligoG CF-5/20 Non-traditional Miscellaneous Alginate oligosaccharide (G-block) fragment Cystic fibrosis Inhalation Phase II NCT03822455 AlgiPharma AS Priority pathogens All critical priority pathogens Critical priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 OligoG CF-5/20 Non-traditional Miscellaneous Alginate oligosaccharide (G-block) fragment Cystic fibrosis Inhalation Phase II NCT03822455 AlgiPharma AS Priority pathogens Acinetobacter baumannii Critical priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 Phage Non-traditional Bacteriophages and phage-derived enzymes Bacteriophage E. coli IV Phase II NCT04287478 "Adaptive Phage Therapeutics" Priority pathogens Streptococcus pneumoniae Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 Phage Non-traditional Bacteriophages and phage-derived enzymes Bacteriophage E. coli IV Phase II NCT04287478 "Adaptive Phage Therapeutics" Priority pathogens Staphylococcus aureus Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 Phage Non-traditional Bacteriophages and phage-derived enzymes Bacteriophage E. coli IV Phase II NCT04287478 "Adaptive Phage Therapeutics" Priority pathogens Pseudomonas aeruginosa Critical priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 Phage Non-traditional Bacteriophages and phage-derived enzymes Bacteriophage E. coli IV Phase II NCT04287478 "Adaptive Phage Therapeutics" Priority pathogens Other priority pathogens Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 Phage Non-traditional Bacteriophages and phage-derived enzymes Bacteriophage E. coli IV Phase II NCT04287478 "Adaptive Phage Therapeutics" Priority pathogens Neisseria gonnorhoeae Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 Phage Non-traditional Bacteriophages and phage-derived enzymes Bacteriophage E. coli IV Phase II NCT04287478 "Adaptive Phage Therapeutics" Priority pathogens Helicobacter pylori Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 Phage Non-traditional Bacteriophages and phage-derived enzymes Bacteriophage E. coli IV Phase II NCT04287478 "Adaptive Phage Therapeutics" Priority pathogens Gram-positive priority pathogens Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 Phage Non-traditional Bacteriophages and phage-derived enzymes Bacteriophage E. coli IV Phase II NCT04287478 "Adaptive Phage Therapeutics" Priority pathogens Enterococcus faecium Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 Phage Non-traditional Bacteriophages and phage-derived enzymes Bacteriophage E. coli IV Phase II NCT04287478 "Adaptive Phage Therapeutics" Priority pathogens Enterobacterales Critical priority pathogens Yes N/A Yes NA NA WHO AMR pipeline analysis Nov-21 Phage Non-traditional Bacteriophages and phage-derived enzymes Bacteriophage E. coli IV Phase II NCT04287478 "Adaptive Phage Therapeutics" Priority pathogens Critical priority pathogens Critical priority pathogens Yes N/A Yes NA NA WHO AMR pipeline analysis Nov-21 Phage Non-traditional Bacteriophages and phage-derived enzymes Bacteriophage E. coli IV Phase II NCT04287478 "Adaptive Phage Therapeutics" Priority pathogens Campylobacter spp. Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 Phage Non-traditional Bacteriophages and phage-derived enzymes Bacteriophage E. coli IV Phase II NCT04287478 "Adaptive Phage Therapeutics" Priority pathogens All critical priority pathogens Critical priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 Phage Non-traditional Bacteriophages and phage-derived enzymes Bacteriophage E. coli IV Phase II NCT04287478 "Adaptive Phage Therapeutics" Priority pathogens Acinetobacter baumannii Critical priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 QPX7728 + QPX2014 - Antibiotics NA Boronate-BLI + undisclosed Gram-negative infections IV Phase I NCT04380207, NCT05072444 Qpex Biopharma Priority pathogens Streptococcus pneumoniae Other priority pathogens N/A Inconclusive Yes NA NA WHO AMR pipeline analysis Nov-21 QPX7728 + QPX2014 - Antibiotics NA Boronate-BLI + undisclosed Gram-negative infections IV Phase I NCT04380207, NCT05072444 Qpex Biopharma Priority pathogens Staphylococcus aureus Other priority pathogens N/A Inconclusive Yes NA NA WHO AMR pipeline analysis Nov-21 QPX7728 + QPX2014 - Antibiotics NA Boronate-BLI + undisclosed Gram-negative infections IV Phase I NCT04380207, NCT05072444 Qpex Biopharma Priority pathogens Pseudomonas aeruginosa Critical priority pathogens Yes Inconclusive Yes NA NA WHO AMR pipeline analysis Nov-21 QPX7728 + QPX2014 - Antibiotics NA Boronate-BLI + undisclosed Gram-negative infections IV Phase I NCT04380207, NCT05072444 Qpex Biopharma Priority pathogens Other priority pathogens Other priority pathogens N/A Inconclusive Yes NA NA WHO AMR pipeline analysis Nov-21 QPX7728 + QPX2014 - Antibiotics NA Boronate-BLI + undisclosed Gram-negative infections IV Phase I NCT04380207, NCT05072444 Qpex Biopharma Priority pathogens Neisseria gonnorhoeae Other priority pathogens N/A Inconclusive Yes NA NA WHO AMR pipeline analysis Nov-21 QPX7728 + QPX2014 - Antibiotics NA Boronate-BLI + undisclosed Gram-negative infections IV Phase I NCT04380207, NCT05072444 Qpex Biopharma Priority pathogens Helicobacter pylori Other priority pathogens N/A Inconclusive Yes NA NA WHO AMR pipeline analysis Nov-21 QPX7728 + QPX2014 - Antibiotics NA Boronate-BLI + undisclosed Gram-negative infections IV Phase I NCT04380207, NCT05072444 Qpex Biopharma Priority pathogens Gram-positive priority pathogens Other priority pathogens N/A Inconclusive Yes NA NA WHO AMR pipeline analysis Nov-21 QPX7728 + QPX2014 - Antibiotics NA Boronate-BLI + undisclosed Gram-negative infections IV Phase I NCT04380207, NCT05072444 Qpex Biopharma Priority pathogens Enterococcus faecium Other priority pathogens N/A Inconclusive Yes NA NA WHO AMR pipeline analysis Nov-21 QPX7728 + QPX2014 - Antibiotics NA Boronate-BLI + undisclosed Gram-negative infections IV Phase I NCT04380207, NCT05072444 Qpex Biopharma Priority pathogens Enterobacterales Critical priority pathogens Yes Inconclusive Yes NA NA WHO AMR pipeline analysis Nov-21 QPX7728 + QPX2014 - Antibiotics NA Boronate-BLI + undisclosed Gram-negative infections IV Phase I NCT04380207, NCT05072444 Qpex Biopharma Priority pathogens Critical priority pathogens Critical priority pathogens Yes Inconclusive Yes NA NA WHO AMR pipeline analysis Nov-21 QPX7728 + QPX2014 - Antibiotics NA Boronate-BLI + undisclosed Gram-negative infections IV Phase I NCT04380207, NCT05072444 Qpex Biopharma Priority pathogens Campylobacter spp. Other priority pathogens N/A Inconclusive Yes NA NA WHO AMR pipeline analysis Nov-21 QPX7728 + QPX2014 - Antibiotics NA Boronate-BLI + undisclosed Gram-negative infections IV Phase I NCT04380207, NCT05072444 Qpex Biopharma Priority pathogens All critical priority pathogens Critical priority pathogens Yes Inconclusive Yes NA NA WHO AMR pipeline analysis Nov-21 QPX7728 + QPX2014 - Antibiotics NA Boronate-BLI + undisclosed Gram-negative infections IV Phase I NCT04380207, NCT05072444 Qpex Biopharma Priority pathogens Acinetobacter baumannii Critical priority pathogens Yes Inconclusive Yes NA NA WHO AMR pipeline analysis Nov-21 QPX7728 + QPX2015 - Antibiotics NA Boronate-BLI + undisclosed Gram-negative infections Oral Phase I NCT03939429 Qpex Biopharma Priority pathogens Streptococcus pneumoniae Other priority pathogens N/A Inconclusive Yes NA NA WHO AMR pipeline analysis Nov-21 QPX7728 + QPX2015 - Antibiotics NA Boronate-BLI + undisclosed Gram-negative infections Oral Phase I NCT03939429 Qpex Biopharma Priority pathogens Staphylococcus aureus Other priority pathogens N/A Inconclusive Yes NA NA WHO AMR pipeline analysis Nov-21 QPX7728 + QPX2015 - Antibiotics NA Boronate-BLI + undisclosed Gram-negative infections Oral Phase I NCT03939429 Qpex Biopharma Priority pathogens Pseudomonas aeruginosa Critical priority pathogens Possibly Inconclusive Yes NA NA WHO AMR pipeline analysis Nov-21 QPX7728 + QPX2015 - Antibiotics NA Boronate-BLI + undisclosed Gram-negative infections Oral Phase I NCT03939429 Qpex Biopharma Priority pathogens Other priority pathogens Other priority pathogens N/A Inconclusive Yes NA NA WHO AMR pipeline analysis Nov-21 QPX7728 + QPX2015 - Antibiotics NA Boronate-BLI + undisclosed Gram-negative infections Oral Phase I NCT03939429 Qpex Biopharma Priority pathogens Neisseria gonnorhoeae Other priority pathogens N/A Inconclusive Yes NA NA WHO AMR pipeline analysis Nov-21 QPX7728 + QPX2015 - Antibiotics NA Boronate-BLI + undisclosed Gram-negative infections Oral Phase I NCT03939429 Qpex Biopharma Priority pathogens Helicobacter pylori Other priority pathogens N/A Inconclusive Yes NA NA WHO AMR pipeline analysis Nov-21 QPX7728 + QPX2015 - Antibiotics NA Boronate-BLI + undisclosed Gram-negative infections Oral Phase I NCT03939429 Qpex Biopharma Priority pathogens Gram-positive priority pathogens Other priority pathogens N/A Inconclusive Yes NA NA WHO AMR pipeline analysis Nov-21 QPX7728 + QPX2015 - Antibiotics NA Boronate-BLI + undisclosed Gram-negative infections Oral Phase I NCT03939429 Qpex Biopharma Priority pathogens Enterococcus faecium Other priority pathogens N/A Inconclusive Yes NA NA WHO AMR pipeline analysis Nov-21 QPX7728 + QPX2015 - Antibiotics NA Boronate-BLI + undisclosed Gram-negative infections Oral Phase I NCT03939429 Qpex Biopharma Priority pathogens Enterobacterales Critical priority pathogens Yes Inconclusive Yes NA NA WHO AMR pipeline analysis Nov-21 QPX7728 + QPX2015 - Antibiotics NA Boronate-BLI + undisclosed Gram-negative infections Oral Phase I NCT03939429 Qpex Biopharma Priority pathogens Critical priority pathogens Critical priority pathogens Yes Inconclusive Yes NA NA WHO AMR pipeline analysis Nov-21 QPX7728 + QPX2015 - Antibiotics NA Boronate-BLI + undisclosed Gram-negative infections Oral Phase I NCT03939429 Qpex Biopharma Priority pathogens Campylobacter spp. Other priority pathogens N/A Inconclusive Yes NA NA WHO AMR pipeline analysis Nov-21 QPX7728 + QPX2015 - Antibiotics NA Boronate-BLI + undisclosed Gram-negative infections Oral Phase I NCT03939429 Qpex Biopharma Priority pathogens All critical priority pathogens Critical priority pathogens Possibly Inconclusive Yes NA NA WHO AMR pipeline analysis Nov-21 QPX7728 + QPX2015 - Antibiotics NA Boronate-BLI + undisclosed Gram-negative infections Oral Phase I NCT03939429 Qpex Biopharma Priority pathogens Acinetobacter baumannii Critical priority pathogens Possibly Inconclusive Yes NA NA WHO AMR pipeline analysis Nov-21 QPX9003 - Antibiotics NA Polymyxin Gram-negative infections IV Phase I NCT04808414 Qpex Biopharma Priority pathogens Streptococcus pneumoniae Other priority pathogens N/A Inconclusive Yes NA NA WHO AMR pipeline analysis Nov-21 QPX9003 - Antibiotics NA Polymyxin Gram-negative infections IV Phase I NCT04808414 Qpex Biopharma Priority pathogens Staphylococcus aureus Other priority pathogens N/A Inconclusive Yes NA NA WHO AMR pipeline analysis Nov-21 QPX9003 - Antibiotics NA Polymyxin Gram-negative infections IV Phase I NCT04808414 Qpex Biopharma Priority pathogens Pseudomonas aeruginosa Critical priority pathogens Possibly Inconclusive Yes NA NA WHO AMR pipeline analysis Nov-21 QPX9003 - Antibiotics NA Polymyxin Gram-negative infections IV Phase I NCT04808414 Qpex Biopharma Priority pathogens Other priority pathogens Other priority pathogens N/A Inconclusive Yes NA NA WHO AMR pipeline analysis Nov-21 QPX9003 - Antibiotics NA Polymyxin Gram-negative infections IV Phase I NCT04808414 Qpex Biopharma Priority pathogens Neisseria gonnorhoeae Other priority pathogens N/A Inconclusive Yes NA NA WHO AMR pipeline analysis Nov-21 QPX9003 - Antibiotics NA Polymyxin Gram-negative infections IV Phase I NCT04808414 Qpex Biopharma Priority pathogens Helicobacter pylori Other priority pathogens N/A Inconclusive Yes NA NA WHO AMR pipeline analysis Nov-21 QPX9003 - Antibiotics NA Polymyxin Gram-negative infections IV Phase I NCT04808414 Qpex Biopharma Priority pathogens Gram-positive priority pathogens Other priority pathogens N/A Inconclusive Yes NA NA WHO AMR pipeline analysis Nov-21 QPX9003 - Antibiotics NA Polymyxin Gram-negative infections IV Phase I NCT04808414 Qpex Biopharma Priority pathogens Enterococcus faecium Other priority pathogens N/A Inconclusive Yes NA NA WHO AMR pipeline analysis Nov-21 QPX9003 - Antibiotics NA Polymyxin Gram-negative infections IV Phase I NCT04808414 Qpex Biopharma Priority pathogens Enterobacterales Critical priority pathogens Possibly Inconclusive Yes NA NA WHO AMR pipeline analysis Nov-21 QPX9003 - Antibiotics NA Polymyxin Gram-negative infections IV Phase I NCT04808414 Qpex Biopharma Priority pathogens Critical priority pathogens Critical priority pathogens Possibly Inconclusive Yes NA NA WHO AMR pipeline analysis Nov-21 QPX9003 - Antibiotics NA Polymyxin Gram-negative infections IV Phase I NCT04808414 Qpex Biopharma Priority pathogens Campylobacter spp. Other priority pathogens N/A Inconclusive Yes NA NA WHO AMR pipeline analysis Nov-21 QPX9003 - Antibiotics NA Polymyxin Gram-negative infections IV Phase I NCT04808414 Qpex Biopharma Priority pathogens All critical priority pathogens Critical priority pathogens Possibly Inconclusive Yes NA NA WHO AMR pipeline analysis Nov-21 QPX9003 - Antibiotics NA Polymyxin Gram-negative infections IV Phase I NCT04808414 Qpex Biopharma Priority pathogens Acinetobacter baumannii Critical priority pathogens Possibly Inconclusive Yes NA NA WHO AMR pipeline analysis Nov-21 RG6006 Abx MCP Antibiotics NA Macrocyclic peptide Acinetobacter infections IV Phase I Not registered Roche Priority pathogens Streptococcus pneumoniae Other priority pathogens N/A Inconclusive Yes NA NA WHO AMR pipeline analysis Nov-21 RG6006 Abx MCP Antibiotics NA Macrocyclic peptide Acinetobacter infections IV Phase I Not registered Roche Priority pathogens Staphylococcus aureus Other priority pathogens N/A Inconclusive Yes NA NA WHO AMR pipeline analysis Nov-21 RG6006 Abx MCP Antibiotics NA Macrocyclic peptide Acinetobacter infections IV Phase I Not registered Roche Priority pathogens Pseudomonas aeruginosa Critical priority pathogens N/A Inconclusive Yes NA NA WHO AMR pipeline analysis Nov-21 RG6006 Abx MCP Antibiotics NA Macrocyclic peptide Acinetobacter infections IV Phase I Not registered Roche Priority pathogens Other priority pathogens Other priority pathogens N/A Inconclusive Yes NA NA WHO AMR pipeline analysis Nov-21 RG6006 Abx MCP Antibiotics NA Macrocyclic peptide Acinetobacter infections IV Phase I Not registered Roche Priority pathogens Neisseria gonnorhoeae Other priority pathogens N/A Inconclusive Yes NA NA WHO AMR pipeline analysis Nov-21 RG6006 Abx MCP Antibiotics NA Macrocyclic peptide Acinetobacter infections IV Phase I Not registered Roche Priority pathogens Helicobacter pylori Other priority pathogens N/A Inconclusive Yes NA NA WHO AMR pipeline analysis Nov-21 RG6006 Abx MCP Antibiotics NA Macrocyclic peptide Acinetobacter infections IV Phase I Not registered Roche Priority pathogens Gram-positive priority pathogens Other priority pathogens N/A Inconclusive Yes NA NA WHO AMR pipeline analysis Nov-21 RG6006 Abx MCP Antibiotics NA Macrocyclic peptide Acinetobacter infections IV Phase I Not registered Roche Priority pathogens Enterococcus faecium Other priority pathogens N/A Inconclusive Yes NA NA WHO AMR pipeline analysis Nov-21 RG6006 Abx MCP Antibiotics NA Macrocyclic peptide Acinetobacter infections IV Phase I Not registered Roche Priority pathogens Enterobacterales Critical priority pathogens N/A Inconclusive Yes NA NA WHO AMR pipeline analysis Nov-21 RG6006 Abx MCP Antibiotics NA Macrocyclic peptide Acinetobacter infections IV Phase I Not registered Roche Priority pathogens Critical priority pathogens Critical priority pathogens Possibly Inconclusive Yes NA NA WHO AMR pipeline analysis Nov-21 RG6006 Abx MCP Antibiotics NA Macrocyclic peptide Acinetobacter infections IV Phase I Not registered Roche Priority pathogens Campylobacter spp. Other priority pathogens N/A Inconclusive Yes NA NA WHO AMR pipeline analysis Nov-21 RG6006 Abx MCP Antibiotics NA Macrocyclic peptide Acinetobacter infections IV Phase I Not registered Roche Priority pathogens All critical priority pathogens Critical priority pathogens N/A Inconclusive Yes NA NA WHO AMR pipeline analysis Nov-21 RG6006 Abx MCP Antibiotics NA Macrocyclic peptide Acinetobacter infections IV Phase I Not registered Roche Priority pathogens Acinetobacter baumannii Critical priority pathogens Possibly Inconclusive Yes NA NA WHO AMR pipeline analysis Nov-21 Rhu-pGSN Rhu-plasma gelsolin Non-traditional Immunomodulating agents Recombinant human plasma gelsolin protein Hospitalized CAP IV Phase II NCT03466073, NCT04358406 BioAegis Therapeutics Priority pathogens Streptococcus pneumoniae Other priority pathogens Yes N/A Yes NA NA WHO AMR pipeline analysis Nov-21 Rhu-pGSN Rhu-plasma gelsolin Non-traditional Immunomodulating agents Recombinant human plasma gelsolin protein Hospitalized CAP IV Phase II NCT03466073, NCT04358406 BioAegis Therapeutics Priority pathogens Staphylococcus aureus Other priority pathogens Yes N/A Yes NA NA WHO AMR pipeline analysis Nov-21 Rhu-pGSN Rhu-plasma gelsolin Non-traditional Immunomodulating agents Recombinant human plasma gelsolin protein Hospitalized CAP IV Phase II NCT03466073, NCT04358406 BioAegis Therapeutics Priority pathogens Pseudomonas aeruginosa Critical priority pathogens Yes N/A Yes NA NA WHO AMR pipeline analysis Nov-21 Rhu-pGSN Rhu-plasma gelsolin Non-traditional Immunomodulating agents Recombinant human plasma gelsolin protein Hospitalized CAP IV Phase II NCT03466073, NCT04358406 BioAegis Therapeutics Priority pathogens Other priority pathogens Other priority pathogens Yes N/A Yes NA NA WHO AMR pipeline analysis Nov-21 Rhu-pGSN Rhu-plasma gelsolin Non-traditional Immunomodulating agents Recombinant human plasma gelsolin protein Hospitalized CAP IV Phase II NCT03466073, NCT04358406 BioAegis Therapeutics Priority pathogens Neisseria gonnorhoeae Other priority pathogens Yes N/A Yes NA NA WHO AMR pipeline analysis Nov-21 Rhu-pGSN Rhu-plasma gelsolin Non-traditional Immunomodulating agents Recombinant human plasma gelsolin protein Hospitalized CAP IV Phase II NCT03466073, NCT04358406 BioAegis Therapeutics Priority pathogens Helicobacter pylori Other priority pathogens Yes N/A Yes NA NA WHO AMR pipeline analysis Nov-21 Rhu-pGSN Rhu-plasma gelsolin Non-traditional Immunomodulating agents Recombinant human plasma gelsolin protein Hospitalized CAP IV Phase II NCT03466073, NCT04358406 BioAegis Therapeutics Priority pathogens Gram-positive priority pathogens Other priority pathogens Yes N/A Yes NA NA WHO AMR pipeline analysis Nov-21 Rhu-pGSN Rhu-plasma gelsolin Non-traditional Immunomodulating agents Recombinant human plasma gelsolin protein Hospitalized CAP IV Phase II NCT03466073, NCT04358406 BioAegis Therapeutics Priority pathogens Enterococcus faecium Other priority pathogens Yes N/A Yes NA NA WHO AMR pipeline analysis Nov-21 Rhu-pGSN Rhu-plasma gelsolin Non-traditional Immunomodulating agents Recombinant human plasma gelsolin protein Hospitalized CAP IV Phase II NCT03466073, NCT04358406 BioAegis Therapeutics Priority pathogens Enterobacterales Critical priority pathogens Yes N/A Yes NA NA WHO AMR pipeline analysis Nov-21 Rhu-pGSN Rhu-plasma gelsolin Non-traditional Immunomodulating agents Recombinant human plasma gelsolin protein Hospitalized CAP IV Phase II NCT03466073, NCT04358406 BioAegis Therapeutics Priority pathogens Critical priority pathogens Critical priority pathogens Yes N/A Yes NA NA WHO AMR pipeline analysis Nov-21 Rhu-pGSN Rhu-plasma gelsolin Non-traditional Immunomodulating agents Recombinant human plasma gelsolin protein Hospitalized CAP IV Phase II NCT03466073, NCT04358406 BioAegis Therapeutics Priority pathogens Campylobacter spp. Other priority pathogens Yes N/A Yes NA NA WHO AMR pipeline analysis Nov-21 Rhu-pGSN Rhu-plasma gelsolin Non-traditional Immunomodulating agents Recombinant human plasma gelsolin protein Hospitalized CAP IV Phase II NCT03466073, NCT04358406 BioAegis Therapeutics Priority pathogens All critical priority pathogens Critical priority pathogens Yes N/A Yes NA NA WHO AMR pipeline analysis Nov-21 Rhu-pGSN Rhu-plasma gelsolin Non-traditional Immunomodulating agents Recombinant human plasma gelsolin protein Hospitalized CAP IV Phase II NCT03466073, NCT04358406 BioAegis Therapeutics Priority pathogens Acinetobacter baumannii Critical priority pathogens Yes N/A Yes NA NA WHO AMR pipeline analysis Nov-21 Solithromycin T-4288 Antibiotics NA Macrolide S. pneumoniae IV & oral Preregistration JapicCTI163439 "Fujfilm Toyama Chemical" Priority pathogens Streptococcus pneumoniae Other priority pathogens Yes No Yes NA NA WHO AMR pipeline analysis Nov-21 Solithromycin T-4288 Antibiotics NA Macrolide S. pneumoniae IV & oral Preregistration JapicCTI163439 "Fujfilm Toyama Chemical" Priority pathogens Staphylococcus aureus Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 Solithromycin T-4288 Antibiotics NA Macrolide S. pneumoniae IV & oral Preregistration JapicCTI163439 "Fujfilm Toyama Chemical" Priority pathogens Pseudomonas aeruginosa Critical priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 Solithromycin T-4288 Antibiotics NA Macrolide S. pneumoniae IV & oral Preregistration JapicCTI163439 "Fujfilm Toyama Chemical" Priority pathogens Other priority pathogens Other priority pathogens Yes No Yes NA NA WHO AMR pipeline analysis Nov-21 Solithromycin T-4288 Antibiotics NA Macrolide S. pneumoniae IV & oral Preregistration JapicCTI163439 "Fujfilm Toyama Chemical" Priority pathogens Neisseria gonnorhoeae Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 Solithromycin T-4288 Antibiotics NA Macrolide S. pneumoniae IV & oral Preregistration JapicCTI163439 "Fujfilm Toyama Chemical" Priority pathogens Helicobacter pylori Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 Solithromycin T-4288 Antibiotics NA Macrolide S. pneumoniae IV & oral Preregistration JapicCTI163439 "Fujfilm Toyama Chemical" Priority pathogens Gram-positive priority pathogens Other priority pathogens Yes No Yes NA NA WHO AMR pipeline analysis Nov-21 Solithromycin T-4288 Antibiotics NA Macrolide S. pneumoniae IV & oral Preregistration JapicCTI163439 "Fujfilm Toyama Chemical" Priority pathogens Enterococcus faecium Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 Solithromycin T-4288 Antibiotics NA Macrolide S. pneumoniae IV & oral Preregistration JapicCTI163439 "Fujfilm Toyama Chemical" Priority pathogens Enterobacterales Critical priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 Solithromycin T-4288 Antibiotics NA Macrolide S. pneumoniae IV & oral Preregistration JapicCTI163439 "Fujfilm Toyama Chemical" Priority pathogens Critical priority pathogens Critical priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 Solithromycin T-4288 Antibiotics NA Macrolide S. pneumoniae IV & oral Preregistration JapicCTI163439 "Fujfilm Toyama Chemical" Priority pathogens Campylobacter spp. Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 Solithromycin T-4288 Antibiotics NA Macrolide S. pneumoniae IV & oral Preregistration JapicCTI163439 "Fujfilm Toyama Chemical" Priority pathogens All critical priority pathogens Critical priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 Solithromycin T-4288 Antibiotics NA Macrolide S. pneumoniae IV & oral Preregistration JapicCTI163439 "Fujfilm Toyama Chemical" Priority pathogens Acinetobacter baumannii Critical priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 SPR-206 Antibiotics NA Polymyxin Acinetobacter infections IV Phase I NCT04865393 Spero Therapeutics Priority pathogens Streptococcus pneumoniae Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 SPR-206 Antibiotics NA Polymyxin Acinetobacter infections IV Phase I NCT04865393 Spero Therapeutics Priority pathogens Staphylococcus aureus Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 SPR-206 Antibiotics NA Polymyxin Acinetobacter infections IV Phase I NCT04865393 Spero Therapeutics Priority pathogens Pseudomonas aeruginosa Critical priority pathogens Yes No Yes NA NA WHO AMR pipeline analysis Nov-21 SPR-206 Antibiotics NA Polymyxin Acinetobacter infections IV Phase I NCT04865393 Spero Therapeutics Priority pathogens Other priority pathogens Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 SPR-206 Antibiotics NA Polymyxin Acinetobacter infections IV Phase I NCT04865393 Spero Therapeutics Priority pathogens Neisseria gonnorhoeae Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 SPR-206 Antibiotics NA Polymyxin Acinetobacter infections IV Phase I NCT04865393 Spero Therapeutics Priority pathogens Helicobacter pylori Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 SPR-206 Antibiotics NA Polymyxin Acinetobacter infections IV Phase I NCT04865393 Spero Therapeutics Priority pathogens Gram-positive priority pathogens Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 SPR-206 Antibiotics NA Polymyxin Acinetobacter infections IV Phase I NCT04865393 Spero Therapeutics Priority pathogens Enterococcus faecium Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 SPR-206 Antibiotics NA Polymyxin Acinetobacter infections IV Phase I NCT04865393 Spero Therapeutics Priority pathogens Enterobacterales Critical priority pathogens Yes No Yes NA NA WHO AMR pipeline analysis Nov-21 SPR-206 Antibiotics NA Polymyxin Acinetobacter infections IV Phase I NCT04865393 Spero Therapeutics Priority pathogens Critical priority pathogens Critical priority pathogens Yes No Yes NA NA WHO AMR pipeline analysis Nov-21 SPR-206 Antibiotics NA Polymyxin Acinetobacter infections IV Phase I NCT04865393 Spero Therapeutics Priority pathogens Campylobacter spp. Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 SPR-206 Antibiotics NA Polymyxin Acinetobacter infections IV Phase I NCT04865393 Spero Therapeutics Priority pathogens All critical priority pathogens Critical priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 SPR-206 Antibiotics NA Polymyxin Acinetobacter infections IV Phase I NCT04865393 Spero Therapeutics Priority pathogens Acinetobacter baumannii Critical priority pathogens Yes No Yes NA NA WHO AMR pipeline analysis Nov-21 Sulopenem, sulopenem etzadroxil/probenecid PF-03709270 Antibiotics NA β-Lactam (penem) uUTI, cUTI, IAI IV, Oral Phase III NCT03354598, NCT03357614, NCT03358576 Iterum Therapeutics Priority pathogens Streptococcus pneumoniae Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 Sulopenem, sulopenem etzadroxil/probenecid PF-03709270 Antibiotics NA β-Lactam (penem) uUTI, cUTI, IAI IV, Oral Phase III NCT03354598, NCT03357614, NCT03358576 Iterum Therapeutics Priority pathogens Staphylococcus aureus Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 Sulopenem, sulopenem etzadroxil/probenecid PF-03709270 Antibiotics NA β-Lactam (penem) uUTI, cUTI, IAI IV, Oral Phase III NCT03354598, NCT03357614, NCT03358576 Iterum Therapeutics Priority pathogens Pseudomonas aeruginosa Critical priority pathogens Possibly No Yes NA NA WHO AMR pipeline analysis Nov-21 Sulopenem, sulopenem etzadroxil/probenecid PF-03709270 Antibiotics NA β-Lactam (penem) uUTI, cUTI, IAI IV, Oral Phase III NCT03354598, NCT03357614, NCT03358576 Iterum Therapeutics Priority pathogens Other priority pathogens Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 Sulopenem, sulopenem etzadroxil/probenecid PF-03709270 Antibiotics NA β-Lactam (penem) uUTI, cUTI, IAI IV, Oral Phase III NCT03354598, NCT03357614, NCT03358576 Iterum Therapeutics Priority pathogens Neisseria gonnorhoeae Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 Sulopenem, sulopenem etzadroxil/probenecid PF-03709270 Antibiotics NA β-Lactam (penem) uUTI, cUTI, IAI IV, Oral Phase III NCT03354598, NCT03357614, NCT03358576 Iterum Therapeutics Priority pathogens Helicobacter pylori Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 Sulopenem, sulopenem etzadroxil/probenecid PF-03709270 Antibiotics NA β-Lactam (penem) uUTI, cUTI, IAI IV, Oral Phase III NCT03354598, NCT03357614, NCT03358576 Iterum Therapeutics Priority pathogens Gram-positive priority pathogens Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 Sulopenem, sulopenem etzadroxil/probenecid PF-03709270 Antibiotics NA β-Lactam (penem) uUTI, cUTI, IAI IV, Oral Phase III NCT03354598, NCT03357614, NCT03358576 Iterum Therapeutics Priority pathogens Enterococcus faecium Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 Sulopenem, sulopenem etzadroxil/probenecid PF-03709270 Antibiotics NA β-Lactam (penem) uUTI, cUTI, IAI IV, Oral Phase III NCT03354598, NCT03357614, NCT03358576 Iterum Therapeutics Priority pathogens Enterobacterales Critical priority pathogens Possibly No Yes NA NA WHO AMR pipeline analysis Nov-21 Sulopenem, sulopenem etzadroxil/probenecid PF-03709270 Antibiotics NA β-Lactam (penem) uUTI, cUTI, IAI IV, Oral Phase III NCT03354598, NCT03357614, NCT03358576 Iterum Therapeutics Priority pathogens Critical priority pathogens Critical priority pathogens Yes No Yes NA NA WHO AMR pipeline analysis Nov-21 Sulopenem, sulopenem etzadroxil/probenecid PF-03709270 Antibiotics NA β-Lactam (penem) uUTI, cUTI, IAI IV, Oral Phase III NCT03354598, NCT03357614, NCT03358576 Iterum Therapeutics Priority pathogens Campylobacter spp. Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 Sulopenem, sulopenem etzadroxil/probenecid PF-03709270 Antibiotics NA β-Lactam (penem) uUTI, cUTI, IAI IV, Oral Phase III NCT03354598, NCT03357614, NCT03358576 Iterum Therapeutics Priority pathogens All critical priority pathogens Critical priority pathogens No No Yes NA NA WHO AMR pipeline analysis Nov-21 Sulopenem, sulopenem etzadroxil/probenecid PF-03709270 Antibiotics NA β-Lactam (penem) uUTI, cUTI, IAI IV, Oral Phase III NCT03354598, NCT03357614, NCT03358576 Iterum Therapeutics Priority pathogens Acinetobacter baumannii Critical priority pathogens Possibly No Yes NA NA WHO AMR pipeline analysis Nov-21 SVT-1C469 - Non-traditional Microbiome-modulating agents Live biotherapeutic product H. pylori Oral Phase I ACTRN12620000923965 Servatus Priority pathogens Streptococcus pneumoniae Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 SVT-1C469 - Non-traditional Microbiome-modulating agents Live biotherapeutic product H. pylori Oral Phase I ACTRN12620000923965 Servatus Priority pathogens Staphylococcus aureus Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 SVT-1C469 - Non-traditional Microbiome-modulating agents Live biotherapeutic product H. pylori Oral Phase I ACTRN12620000923965 Servatus Priority pathogens Pseudomonas aeruginosa Critical priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 SVT-1C469 - Non-traditional Microbiome-modulating agents Live biotherapeutic product H. pylori Oral Phase I ACTRN12620000923965 Servatus Priority pathogens Other priority pathogens Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 SVT-1C469 - Non-traditional Microbiome-modulating agents Live biotherapeutic product H. pylori Oral Phase I ACTRN12620000923965 Servatus Priority pathogens Neisseria gonnorhoeae Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 SVT-1C469 - Non-traditional Microbiome-modulating agents Live biotherapeutic product H. pylori Oral Phase I ACTRN12620000923965 Servatus Priority pathogens Helicobacter pylori Other priority pathogens Yes N/A Yes NA NA WHO AMR pipeline analysis Nov-21 SVT-1C469 - Non-traditional Microbiome-modulating agents Live biotherapeutic product H. pylori Oral Phase I ACTRN12620000923965 Servatus Priority pathogens Gram-positive priority pathogens Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 SVT-1C469 - Non-traditional Microbiome-modulating agents Live biotherapeutic product H. pylori Oral Phase I ACTRN12620000923965 Servatus Priority pathogens Enterococcus faecium Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 SVT-1C469 - Non-traditional Microbiome-modulating agents Live biotherapeutic product H. pylori Oral Phase I ACTRN12620000923965 Servatus Priority pathogens Enterobacterales Critical priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 SVT-1C469 - Non-traditional Microbiome-modulating agents Live biotherapeutic product H. pylori Oral Phase I ACTRN12620000923965 Servatus Priority pathogens Critical priority pathogens Critical priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 SVT-1C469 - Non-traditional Microbiome-modulating agents Live biotherapeutic product H. pylori Oral Phase I ACTRN12620000923965 Servatus Priority pathogens Campylobacter spp. Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 SVT-1C469 - Non-traditional Microbiome-modulating agents Live biotherapeutic product H. pylori Oral Phase I ACTRN12620000923965 Servatus Priority pathogens All critical priority pathogens Critical priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 SVT-1C469 - Non-traditional Microbiome-modulating agents Live biotherapeutic product H. pylori Oral Phase I ACTRN12620000923965 Servatus Priority pathogens Acinetobacter baumannii Critical priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 Taniborbactam + cefepime VNRX-5133 + cefepime Antibiotics NA Boronate BLI + β-lactam (cephalosporin) cUTI and AP IV Phase III NCT03840148 VenatoRx Pharmaceuticals, Inc/ GARDP Priority pathogens Streptococcus pneumoniae Other priority pathogens N/A Yes Yes NA NA WHO AMR pipeline analysis Nov-21 Taniborbactam + cefepime VNRX-5133 + cefepime Antibiotics NA Boronate BLI + β-lactam (cephalosporin) cUTI and AP IV Phase III NCT03840148 VenatoRx Pharmaceuticals, Inc/ GARDP Priority pathogens Staphylococcus aureus Other priority pathogens N/A Yes Yes NA NA WHO AMR pipeline analysis Nov-21 Taniborbactam + cefepime VNRX-5133 + cefepime Antibiotics NA Boronate BLI + β-lactam (cephalosporin) cUTI and AP IV Phase III NCT03840148 VenatoRx Pharmaceuticals, Inc/ GARDP Priority pathogens Pseudomonas aeruginosa Critical priority pathogens Yes Yes Yes NA NA WHO AMR pipeline analysis Nov-21 Taniborbactam + cefepime VNRX-5133 + cefepime Antibiotics NA Boronate BLI + β-lactam (cephalosporin) cUTI and AP IV Phase III NCT03840148 VenatoRx Pharmaceuticals, Inc/ GARDP Priority pathogens Other priority pathogens Other priority pathogens N/A Yes Yes NA NA WHO AMR pipeline analysis Nov-21 Taniborbactam + cefepime VNRX-5133 + cefepime Antibiotics NA Boronate BLI + β-lactam (cephalosporin) cUTI and AP IV Phase III NCT03840148 VenatoRx Pharmaceuticals, Inc/ GARDP Priority pathogens Neisseria gonnorhoeae Other priority pathogens N/A Yes Yes NA NA WHO AMR pipeline analysis Nov-21 Taniborbactam + cefepime VNRX-5133 + cefepime Antibiotics NA Boronate BLI + β-lactam (cephalosporin) cUTI and AP IV Phase III NCT03840148 VenatoRx Pharmaceuticals, Inc/ GARDP Priority pathogens Helicobacter pylori Other priority pathogens N/A Yes Yes NA NA WHO AMR pipeline analysis Nov-21 Taniborbactam + cefepime VNRX-5133 + cefepime Antibiotics NA Boronate BLI + β-lactam (cephalosporin) cUTI and AP IV Phase III NCT03840148 VenatoRx Pharmaceuticals, Inc/ GARDP Priority pathogens Gram-positive priority pathogens Other priority pathogens N/A Yes Yes NA NA WHO AMR pipeline analysis Nov-21 Taniborbactam + cefepime VNRX-5133 + cefepime Antibiotics NA Boronate BLI + β-lactam (cephalosporin) cUTI and AP IV Phase III NCT03840148 VenatoRx Pharmaceuticals, Inc/ GARDP Priority pathogens Enterococcus faecium Other priority pathogens N/A Yes Yes NA NA WHO AMR pipeline analysis Nov-21 Taniborbactam + cefepime VNRX-5133 + cefepime Antibiotics NA Boronate BLI + β-lactam (cephalosporin) cUTI and AP IV Phase III NCT03840148 VenatoRx Pharmaceuticals, Inc/ GARDP Priority pathogens Enterobacterales Critical priority pathogens Yes Yes Yes NA NA WHO AMR pipeline analysis Nov-21 Taniborbactam + cefepime VNRX-5133 + cefepime Antibiotics NA Boronate BLI + β-lactam (cephalosporin) cUTI and AP IV Phase III NCT03840148 VenatoRx Pharmaceuticals, Inc/ GARDP Priority pathogens Critical priority pathogens Critical priority pathogens Yes Yes Yes NA NA WHO AMR pipeline analysis Nov-21 Taniborbactam + cefepime VNRX-5133 + cefepime Antibiotics NA Boronate BLI + β-lactam (cephalosporin) cUTI and AP IV Phase III NCT03840148 VenatoRx Pharmaceuticals, Inc/ GARDP Priority pathogens Campylobacter spp. Other priority pathogens N/A Yes Yes NA NA WHO AMR pipeline analysis Nov-21 Taniborbactam + cefepime VNRX-5133 + cefepime Antibiotics NA Boronate BLI + β-lactam (cephalosporin) cUTI and AP IV Phase III NCT03840148 VenatoRx Pharmaceuticals, Inc/ GARDP Priority pathogens All critical priority pathogens Critical priority pathogens No Yes Yes NA NA WHO AMR pipeline analysis Nov-21 Taniborbactam + cefepime VNRX-5133 + cefepime Antibiotics NA Boronate BLI + β-lactam (cephalosporin) cUTI and AP IV Phase III NCT03840148 VenatoRx Pharmaceuticals, Inc/ GARDP Priority pathogens Acinetobacter baumannii Critical priority pathogens Possibly Yes Yes NA NA WHO AMR pipeline analysis Nov-21 TNP-2092 – Antibiotics NA Rifamycin-quinolizinone hybrid Gastrointestinal infections (caused by S. aureus and H. pylori) IV, Oral Phase II NCT03964493 Tennor Therapeutics Priority pathogens Streptococcus pneumoniae Other priority pathogens N/A No Yes NA ? WHO AMR pipeline analysis Nov-21 TNP-2092 – Antibiotics NA Rifamycin-quinolizinone hybrid Gastrointestinal infections (caused by S. aureus and H. pylori) IV, Oral Phase II NCT03964493 Tennor Therapeutics Priority pathogens Staphylococcus aureus Other priority pathogens Possibly No Yes NA ? WHO AMR pipeline analysis Nov-21 TNP-2092 – Antibiotics NA Rifamycin-quinolizinone hybrid Gastrointestinal infections (caused by S. aureus and H. pylori) IV, Oral Phase II NCT03964493 Tennor Therapeutics Priority pathogens Pseudomonas aeruginosa Critical priority pathogens No No Yes NA ? WHO AMR pipeline analysis Nov-21 TNP-2092 – Antibiotics NA Rifamycin-quinolizinone hybrid Gastrointestinal infections (caused by S. aureus and H. pylori) IV, Oral Phase II NCT03964493 Tennor Therapeutics Priority pathogens Other priority pathogens Other priority pathogens Possibly No Yes NA ? WHO AMR pipeline analysis Nov-21 TNP-2092 – Antibiotics NA Rifamycin-quinolizinone hybrid Gastrointestinal infections (caused by S. aureus and H. pylori) IV, Oral Phase II NCT03964493 Tennor Therapeutics Priority pathogens Neisseria gonnorhoeae Other priority pathogens No No Yes NA ? WHO AMR pipeline analysis Nov-21 TNP-2092 – Antibiotics NA Rifamycin-quinolizinone hybrid Gastrointestinal infections (caused by S. aureus and H. pylori) IV, Oral Phase II NCT03964493 Tennor Therapeutics Priority pathogens Helicobacter pylori Other priority pathogens Possibly No Yes NA ? WHO AMR pipeline analysis Nov-21 TNP-2092 – Antibiotics NA Rifamycin-quinolizinone hybrid Gastrointestinal infections (caused by S. aureus and H. pylori) IV, Oral Phase II NCT03964493 Tennor Therapeutics Priority pathogens Gram-positive priority pathogens Other priority pathogens Possibly No Yes NA ? WHO AMR pipeline analysis Nov-21 TNP-2092 – Antibiotics NA Rifamycin-quinolizinone hybrid Gastrointestinal infections (caused by S. aureus and H. pylori) IV, Oral Phase II NCT03964493 Tennor Therapeutics Priority pathogens Enterococcus faecium Other priority pathogens Possibly No Yes NA ? WHO AMR pipeline analysis Nov-21 TNP-2092 – Antibiotics NA Rifamycin-quinolizinone hybrid Gastrointestinal infections (caused by S. aureus and H. pylori) IV, Oral Phase II NCT03964493 Tennor Therapeutics Priority pathogens Enterobacterales Critical priority pathogens No No Yes NA ? WHO AMR pipeline analysis Nov-21 TNP-2092 – Antibiotics NA Rifamycin-quinolizinone hybrid Gastrointestinal infections (caused by S. aureus and H. pylori) IV, Oral Phase II NCT03964493 Tennor Therapeutics Priority pathogens Critical priority pathogens Critical priority pathogens No No Yes NA ? WHO AMR pipeline analysis Nov-21 TNP-2092 – Antibiotics NA Rifamycin-quinolizinone hybrid Gastrointestinal infections (caused by S. aureus and H. pylori) IV, Oral Phase II NCT03964493 Tennor Therapeutics Priority pathogens Campylobacter spp. Other priority pathogens N/A No Yes NA ? WHO AMR pipeline analysis Nov-21 TNP-2092 – Antibiotics NA Rifamycin-quinolizinone hybrid Gastrointestinal infections (caused by S. aureus and H. pylori) IV, Oral Phase II NCT03964493 Tennor Therapeutics Priority pathogens All critical priority pathogens Critical priority pathogens No No Yes NA ? WHO AMR pipeline analysis Nov-21 TNP-2092 – Antibiotics NA Rifamycin-quinolizinone hybrid Gastrointestinal infections (caused by S. aureus and H. pylori) IV, Oral Phase II NCT03964493 Tennor Therapeutics Priority pathogens Acinetobacter baumannii Critical priority pathogens No No Yes NA ? WHO AMR pipeline analysis Nov-21 TNP-2198 - Antibiotics NA rifamycin-nitroimidazole conjugate Helicobacter pylori infection, Clostridioides difficile infection, and bacterial vaginosis Oral Phase II CTR20190734 TenNor Therapeutics Priority pathogens Streptococcus pneumoniae Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 TNP-2198 - Antibiotics NA rifamycin-nitroimidazole conjugate Helicobacter pylori infection, Clostridioides difficile infection, and bacterial vaginosis Oral Phase II CTR20190734 TenNor Therapeutics Priority pathogens Staphylococcus aureus Other priority pathogens No No Yes NA NA WHO AMR pipeline analysis Nov-21 TNP-2198 - Antibiotics NA rifamycin-nitroimidazole conjugate Helicobacter pylori infection, Clostridioides difficile infection, and bacterial vaginosis Oral Phase II CTR20190734 TenNor Therapeutics Priority pathogens Pseudomonas aeruginosa Critical priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 TNP-2198 - Antibiotics NA rifamycin-nitroimidazole conjugate Helicobacter pylori infection, Clostridioides difficile infection, and bacterial vaginosis Oral Phase II CTR20190734 TenNor Therapeutics Priority pathogens Other priority pathogens Other priority pathogens Yes No Yes NA NA WHO AMR pipeline analysis Nov-21 TNP-2198 - Antibiotics NA rifamycin-nitroimidazole conjugate Helicobacter pylori infection, Clostridioides difficile infection, and bacterial vaginosis Oral Phase II CTR20190734 TenNor Therapeutics Priority pathogens Neisseria gonnorhoeae Other priority pathogens Possibly No Yes NA NA WHO AMR pipeline analysis Nov-21 TNP-2198 - Antibiotics NA rifamycin-nitroimidazole conjugate Helicobacter pylori infection, Clostridioides difficile infection, and bacterial vaginosis Oral Phase II CTR20190734 TenNor Therapeutics Priority pathogens Helicobacter pylori Other priority pathogens Yes No Yes NA NA WHO AMR pipeline analysis Nov-21 TNP-2198 - Antibiotics NA rifamycin-nitroimidazole conjugate Helicobacter pylori infection, Clostridioides difficile infection, and bacterial vaginosis Oral Phase II CTR20190734 TenNor Therapeutics Priority pathogens Gram-positive priority pathogens Other priority pathogens No No Yes NA NA WHO AMR pipeline analysis Nov-21 TNP-2198 - Antibiotics NA rifamycin-nitroimidazole conjugate Helicobacter pylori infection, Clostridioides difficile infection, and bacterial vaginosis Oral Phase II CTR20190734 TenNor Therapeutics Priority pathogens Enterococcus faecium Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 TNP-2198 - Antibiotics NA rifamycin-nitroimidazole conjugate Helicobacter pylori infection, Clostridioides difficile infection, and bacterial vaginosis Oral Phase II CTR20190734 TenNor Therapeutics Priority pathogens Enterobacterales Critical priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 TNP-2198 - Antibiotics NA rifamycin-nitroimidazole conjugate Helicobacter pylori infection, Clostridioides difficile infection, and bacterial vaginosis Oral Phase II CTR20190734 TenNor Therapeutics Priority pathogens Critical priority pathogens Critical priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 TNP-2198 - Antibiotics NA rifamycin-nitroimidazole conjugate Helicobacter pylori infection, Clostridioides difficile infection, and bacterial vaginosis Oral Phase II CTR20190734 TenNor Therapeutics Priority pathogens Campylobacter spp. Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 TNP-2198 - Antibiotics NA rifamycin-nitroimidazole conjugate Helicobacter pylori infection, Clostridioides difficile infection, and bacterial vaginosis Oral Phase II CTR20190734 TenNor Therapeutics Priority pathogens All critical priority pathogens Critical priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 TNP-2198 - Antibiotics NA rifamycin-nitroimidazole conjugate Helicobacter pylori infection, Clostridioides difficile infection, and bacterial vaginosis Oral Phase II CTR20190734 TenNor Therapeutics Priority pathogens Acinetobacter baumannii Critical priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 TRL1068 - Non-traditional Antibodies Antibody Gram-negative and Gram-positive bacterial infections IV Phase I NCT04763759 Trellis Bioscience Priority pathogens Streptococcus pneumoniae Other priority pathogens Yes N/A Yes NA NA WHO AMR pipeline analysis Nov-21 TRL1068 - Non-traditional Antibodies Antibody Gram-negative and Gram-positive bacterial infections IV Phase I NCT04763759 Trellis Bioscience Priority pathogens Staphylococcus aureus Other priority pathogens Yes N/A Yes NA NA WHO AMR pipeline analysis Nov-21 TRL1068 - Non-traditional Antibodies Antibody Gram-negative and Gram-positive bacterial infections IV Phase I NCT04763759 Trellis Bioscience Priority pathogens Pseudomonas aeruginosa Critical priority pathogens Yes N/A Yes NA NA WHO AMR pipeline analysis Nov-21 TRL1068 - Non-traditional Antibodies Antibody Gram-negative and Gram-positive bacterial infections IV Phase I NCT04763759 Trellis Bioscience Priority pathogens Other priority pathogens Other priority pathogens Yes N/A Yes NA NA WHO AMR pipeline analysis Nov-21 TRL1068 - Non-traditional Antibodies Antibody Gram-negative and Gram-positive bacterial infections IV Phase I NCT04763759 Trellis Bioscience Priority pathogens Neisseria gonnorhoeae Other priority pathogens Yes N/A Yes NA NA WHO AMR pipeline analysis Nov-21 TRL1068 - Non-traditional Antibodies Antibody Gram-negative and Gram-positive bacterial infections IV Phase I NCT04763759 Trellis Bioscience Priority pathogens Helicobacter pylori Other priority pathogens Possibly N/A Yes NA NA WHO AMR pipeline analysis Nov-21 TRL1068 - Non-traditional Antibodies Antibody Gram-negative and Gram-positive bacterial infections IV Phase I NCT04763759 Trellis Bioscience Priority pathogens Gram-positive priority pathogens Other priority pathogens Yes N/A Yes NA NA WHO AMR pipeline analysis Nov-21 TRL1068 - Non-traditional Antibodies Antibody Gram-negative and Gram-positive bacterial infections IV Phase I NCT04763759 Trellis Bioscience Priority pathogens Enterococcus faecium Other priority pathogens Yes N/A Yes NA NA WHO AMR pipeline analysis Nov-21 TRL1068 - Non-traditional Antibodies Antibody Gram-negative and Gram-positive bacterial infections IV Phase I NCT04763759 Trellis Bioscience Priority pathogens Enterobacterales Critical priority pathogens Yes N/A Yes NA NA WHO AMR pipeline analysis Nov-21 TRL1068 - Non-traditional Antibodies Antibody Gram-negative and Gram-positive bacterial infections IV Phase I NCT04763759 Trellis Bioscience Priority pathogens Critical priority pathogens Critical priority pathogens Yes N/A Yes NA NA WHO AMR pipeline analysis Nov-21 TRL1068 - Non-traditional Antibodies Antibody Gram-negative and Gram-positive bacterial infections IV Phase I NCT04763759 Trellis Bioscience Priority pathogens Campylobacter spp. Other priority pathogens Possibly N/A Yes NA NA WHO AMR pipeline analysis Nov-21 TRL1068 - Non-traditional Antibodies Antibody Gram-negative and Gram-positive bacterial infections IV Phase I NCT04763759 Trellis Bioscience Priority pathogens All critical priority pathogens Critical priority pathogens Yes N/A Yes NA NA WHO AMR pipeline analysis Nov-21 TRL1068 - Non-traditional Antibodies Antibody Gram-negative and Gram-positive bacterial infections IV Phase I NCT04763759 Trellis Bioscience Priority pathogens Acinetobacter baumannii Critical priority pathogens Yes N/A Yes NA NA WHO AMR pipeline analysis Nov-21 TXA709 - Antibiotics NA Diflurobenzamide (FtsZ inhibitor) MRSA IV, Oral Phase I Not registered TAXIS Pharmaceuticals Priority pathogens Streptococcus pneumoniae Other priority pathogens No Yes Yes NA NA WHO AMR pipeline analysis Nov-21 TXA709 - Antibiotics NA Diflurobenzamide (FtsZ inhibitor) MRSA IV, Oral Phase I Not registered TAXIS Pharmaceuticals Priority pathogens Staphylococcus aureus Other priority pathogens Yes Yes Yes NA NA WHO AMR pipeline analysis Nov-21 TXA709 - Antibiotics NA Diflurobenzamide (FtsZ inhibitor) MRSA IV, Oral Phase I Not registered TAXIS Pharmaceuticals Priority pathogens Pseudomonas aeruginosa Critical priority pathogens No Yes Yes NA NA WHO AMR pipeline analysis Nov-21 TXA709 - Antibiotics NA Diflurobenzamide (FtsZ inhibitor) MRSA IV, Oral Phase I Not registered TAXIS Pharmaceuticals Priority pathogens Other priority pathogens Other priority pathogens Yes Yes Yes NA NA WHO AMR pipeline analysis Nov-21 TXA709 - Antibiotics NA Diflurobenzamide (FtsZ inhibitor) MRSA IV, Oral Phase I Not registered TAXIS Pharmaceuticals Priority pathogens Neisseria gonnorhoeae Other priority pathogens No Yes Yes NA NA WHO AMR pipeline analysis Nov-21 TXA709 - Antibiotics NA Diflurobenzamide (FtsZ inhibitor) MRSA IV, Oral Phase I Not registered TAXIS Pharmaceuticals Priority pathogens Helicobacter pylori Other priority pathogens No Yes Yes NA NA WHO AMR pipeline analysis Nov-21 TXA709 - Antibiotics NA Diflurobenzamide (FtsZ inhibitor) MRSA IV, Oral Phase I Not registered TAXIS Pharmaceuticals Priority pathogens Gram-positive priority pathogens Other priority pathogens Yes Yes Yes NA NA WHO AMR pipeline analysis Nov-21 TXA709 - Antibiotics NA Diflurobenzamide (FtsZ inhibitor) MRSA IV, Oral Phase I Not registered TAXIS Pharmaceuticals Priority pathogens Enterococcus faecium Other priority pathogens No Yes Yes NA NA WHO AMR pipeline analysis Nov-21 TXA709 - Antibiotics NA Diflurobenzamide (FtsZ inhibitor) MRSA IV, Oral Phase I Not registered TAXIS Pharmaceuticals Priority pathogens Enterobacterales Critical priority pathogens Possibly Yes Yes NA NA WHO AMR pipeline analysis Nov-21 TXA709 - Antibiotics NA Diflurobenzamide (FtsZ inhibitor) MRSA IV, Oral Phase I Not registered TAXIS Pharmaceuticals Priority pathogens Critical priority pathogens Critical priority pathogens Yes Yes Yes NA NA WHO AMR pipeline analysis Nov-21 TXA709 - Antibiotics NA Diflurobenzamide (FtsZ inhibitor) MRSA IV, Oral Phase I Not registered TAXIS Pharmaceuticals Priority pathogens Campylobacter spp. Other priority pathogens No Yes Yes NA NA WHO AMR pipeline analysis Nov-21 TXA709 - Antibiotics NA Diflurobenzamide (FtsZ inhibitor) MRSA IV, Oral Phase I Not registered TAXIS Pharmaceuticals Priority pathogens All critical priority pathogens Critical priority pathogens No Yes Yes NA NA WHO AMR pipeline analysis Nov-21 TXA709 - Antibiotics NA Diflurobenzamide (FtsZ inhibitor) MRSA IV, Oral Phase I Not registered TAXIS Pharmaceuticals Priority pathogens Acinetobacter baumannii Critical priority pathogens Possibly Yes Yes NA NA WHO AMR pipeline analysis Nov-21 VNRX-7145 + ceftibuten – Antibiotics NA Boronate-BLI + cephalosporin Gram-negative infections Oral Phase I NCT04243863 Venatorx Priority pathogens Streptococcus pneumoniae Other priority pathogens N/A Yes Yes NA NA WHO AMR pipeline analysis Nov-21 VNRX-7145 + ceftibuten – Antibiotics NA Boronate-BLI + cephalosporin Gram-negative infections Oral Phase I NCT04243863 Venatorx Priority pathogens Staphylococcus aureus Other priority pathogens N/A Yes Yes NA NA WHO AMR pipeline analysis Nov-21 VNRX-7145 + ceftibuten – Antibiotics NA Boronate-BLI + cephalosporin Gram-negative infections Oral Phase I NCT04243863 Venatorx Priority pathogens Pseudomonas aeruginosa Critical priority pathogens Possibly Yes Yes NA NA WHO AMR pipeline analysis Nov-21 VNRX-7145 + ceftibuten – Antibiotics NA Boronate-BLI + cephalosporin Gram-negative infections Oral Phase I NCT04243863 Venatorx Priority pathogens Other priority pathogens Other priority pathogens N/A Yes Yes NA NA WHO AMR pipeline analysis Nov-21 VNRX-7145 + ceftibuten – Antibiotics NA Boronate-BLI + cephalosporin Gram-negative infections Oral Phase I NCT04243863 Venatorx Priority pathogens Neisseria gonnorhoeae Other priority pathogens N/A Yes Yes NA NA WHO AMR pipeline analysis Nov-21 VNRX-7145 + ceftibuten – Antibiotics NA Boronate-BLI + cephalosporin Gram-negative infections Oral Phase I NCT04243863 Venatorx Priority pathogens Helicobacter pylori Other priority pathogens N/A Yes Yes NA NA WHO AMR pipeline analysis Nov-21 VNRX-7145 + ceftibuten – Antibiotics NA Boronate-BLI + cephalosporin Gram-negative infections Oral Phase I NCT04243863 Venatorx Priority pathogens Gram-positive priority pathogens Other priority pathogens N/A Yes Yes NA NA WHO AMR pipeline analysis Nov-21 VNRX-7145 + ceftibuten – Antibiotics NA Boronate-BLI + cephalosporin Gram-negative infections Oral Phase I NCT04243863 Venatorx Priority pathogens Enterococcus faecium Other priority pathogens N/A Yes Yes NA NA WHO AMR pipeline analysis Nov-21 VNRX-7145 + ceftibuten – Antibiotics NA Boronate-BLI + cephalosporin Gram-negative infections Oral Phase I NCT04243863 Venatorx Priority pathogens Enterobacterales Critical priority pathogens Yes Yes Yes NA NA WHO AMR pipeline analysis Nov-21 VNRX-7145 + ceftibuten – Antibiotics NA Boronate-BLI + cephalosporin Gram-negative infections Oral Phase I NCT04243863 Venatorx Priority pathogens Critical priority pathogens Critical priority pathogens Yes Yes Yes NA NA WHO AMR pipeline analysis Nov-21 VNRX-7145 + ceftibuten – Antibiotics NA Boronate-BLI + cephalosporin Gram-negative infections Oral Phase I NCT04243863 Venatorx Priority pathogens Campylobacter spp. Other priority pathogens N/A Yes Yes NA NA WHO AMR pipeline analysis Nov-21 VNRX-7145 + ceftibuten – Antibiotics NA Boronate-BLI + cephalosporin Gram-negative infections Oral Phase I NCT04243863 Venatorx Priority pathogens All critical priority pathogens Critical priority pathogens No Yes Yes NA NA WHO AMR pipeline analysis Nov-21 VNRX-7145 + ceftibuten – Antibiotics NA Boronate-BLI + cephalosporin Gram-negative infections Oral Phase I NCT04243863 Venatorx Priority pathogens Acinetobacter baumannii Critical priority pathogens Possibly Yes Yes NA NA WHO AMR pipeline analysis Nov-21 "XNW4107 +imipenem + cilastin" - Antibiotics NA "BLI + carbapenem + degradation inhibitor" HABP/VABP IV Phase I NCT04802863, NCT04482569 Sinovent Priority pathogens Streptococcus pneumoniae Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 "XNW4107 +imipenem + cilastin" - Antibiotics NA "BLI + carbapenem + degradation inhibitor" HABP/VABP IV Phase I NCT04802863, NCT04482569 Sinovent Priority pathogens Staphylococcus aureus Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 "XNW4107 +imipenem + cilastin" - Antibiotics NA "BLI + carbapenem + degradation inhibitor" HABP/VABP IV Phase I NCT04802863, NCT04482569 Sinovent Priority pathogens Pseudomonas aeruginosa Critical priority pathogens Possibly No Yes NA NA WHO AMR pipeline analysis Nov-21 "XNW4107 +imipenem + cilastin" - Antibiotics NA "BLI + carbapenem + degradation inhibitor" HABP/VABP IV Phase I NCT04802863, NCT04482569 Sinovent Priority pathogens Other priority pathogens Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 "XNW4107 +imipenem + cilastin" - Antibiotics NA "BLI + carbapenem + degradation inhibitor" HABP/VABP IV Phase I NCT04802863, NCT04482569 Sinovent Priority pathogens Neisseria gonnorhoeae Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 "XNW4107 +imipenem + cilastin" - Antibiotics NA "BLI + carbapenem + degradation inhibitor" HABP/VABP IV Phase I NCT04802863, NCT04482569 Sinovent Priority pathogens Helicobacter pylori Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 "XNW4107 +imipenem + cilastin" - Antibiotics NA "BLI + carbapenem + degradation inhibitor" HABP/VABP IV Phase I NCT04802863, NCT04482569 Sinovent Priority pathogens Gram-positive priority pathogens Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 "XNW4107 +imipenem + cilastin" - Antibiotics NA "BLI + carbapenem + degradation inhibitor" HABP/VABP IV Phase I NCT04802863, NCT04482569 Sinovent Priority pathogens Enterococcus faecium Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 "XNW4107 +imipenem + cilastin" - Antibiotics NA "BLI + carbapenem + degradation inhibitor" HABP/VABP IV Phase I NCT04802863, NCT04482569 Sinovent Priority pathogens Enterobacterales Critical priority pathogens Possibly No Yes NA NA WHO AMR pipeline analysis Nov-21 "XNW4107 +imipenem + cilastin" - Antibiotics NA "BLI + carbapenem + degradation inhibitor" HABP/VABP IV Phase I NCT04802863, NCT04482569 Sinovent Priority pathogens Critical priority pathogens Critical priority pathogens Possibly No Yes NA NA WHO AMR pipeline analysis Nov-21 "XNW4107 +imipenem + cilastin" - Antibiotics NA "BLI + carbapenem + degradation inhibitor" HABP/VABP IV Phase I NCT04802863, NCT04482569 Sinovent Priority pathogens Campylobacter spp. Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 "XNW4107 +imipenem + cilastin" - Antibiotics NA "BLI + carbapenem + degradation inhibitor" HABP/VABP IV Phase I NCT04802863, NCT04482569 Sinovent Priority pathogens All critical priority pathogens Critical priority pathogens Possibly No Yes NA NA WHO AMR pipeline analysis Nov-21 "XNW4107 +imipenem + cilastin" - Antibiotics NA "BLI + carbapenem + degradation inhibitor" HABP/VABP IV Phase I NCT04802863, NCT04482569 Sinovent Priority pathogens Acinetobacter baumannii Critical priority pathogens Possibly No Yes NA NA WHO AMR pipeline analysis Nov-21 YPT-01 - Non-traditional Bacteriophages and phage-derived enzymes Bacteriophage CF subjects with P. aeruginosa infections Inhalation Phase II NCT04684641 Felix Biotechnology/ Yale University Priority pathogens Streptococcus pneumoniae Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 YPT-01 - Non-traditional Bacteriophages and phage-derived enzymes Bacteriophage CF subjects with P. aeruginosa infections Inhalation Phase II NCT04684641 Felix Biotechnology/ Yale University Priority pathogens Staphylococcus aureus Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 YPT-01 - Non-traditional Bacteriophages and phage-derived enzymes Bacteriophage CF subjects with P. aeruginosa infections Inhalation Phase II NCT04684641 Felix Biotechnology/ Yale University Priority pathogens Pseudomonas aeruginosa Critical priority pathogens Yes N/A Yes NA NA WHO AMR pipeline analysis Nov-21 YPT-01 - Non-traditional Bacteriophages and phage-derived enzymes Bacteriophage CF subjects with P. aeruginosa infections Inhalation Phase II NCT04684641 Felix Biotechnology/ Yale University Priority pathogens Other priority pathogens Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 YPT-01 - Non-traditional Bacteriophages and phage-derived enzymes Bacteriophage CF subjects with P. aeruginosa infections Inhalation Phase II NCT04684641 Felix Biotechnology/ Yale University Priority pathogens Neisseria gonnorhoeae Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 YPT-01 - Non-traditional Bacteriophages and phage-derived enzymes Bacteriophage CF subjects with P. aeruginosa infections Inhalation Phase II NCT04684641 Felix Biotechnology/ Yale University Priority pathogens Helicobacter pylori Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 YPT-01 - Non-traditional Bacteriophages and phage-derived enzymes Bacteriophage CF subjects with P. aeruginosa infections Inhalation Phase II NCT04684641 Felix Biotechnology/ Yale University Priority pathogens Gram-positive priority pathogens Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 YPT-01 - Non-traditional Bacteriophages and phage-derived enzymes Bacteriophage CF subjects with P. aeruginosa infections Inhalation Phase II NCT04684641 Felix Biotechnology/ Yale University Priority pathogens Enterococcus faecium Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 YPT-01 - Non-traditional Bacteriophages and phage-derived enzymes Bacteriophage CF subjects with P. aeruginosa infections Inhalation Phase II NCT04684641 Felix Biotechnology/ Yale University Priority pathogens Enterobacterales Critical priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 YPT-01 - Non-traditional Bacteriophages and phage-derived enzymes Bacteriophage CF subjects with P. aeruginosa infections Inhalation Phase II NCT04684641 Felix Biotechnology/ Yale University Priority pathogens Critical priority pathogens Critical priority pathogens Yes N/A Yes NA NA WHO AMR pipeline analysis Nov-21 YPT-01 - Non-traditional Bacteriophages and phage-derived enzymes Bacteriophage CF subjects with P. aeruginosa infections Inhalation Phase II NCT04684641 Felix Biotechnology/ Yale University Priority pathogens Campylobacter spp. Other priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 YPT-01 - Non-traditional Bacteriophages and phage-derived enzymes Bacteriophage CF subjects with P. aeruginosa infections Inhalation Phase II NCT04684641 Felix Biotechnology/ Yale University Priority pathogens All critical priority pathogens Critical priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 YPT-01 - Non-traditional Bacteriophages and phage-derived enzymes Bacteriophage CF subjects with P. aeruginosa infections Inhalation Phase II NCT04684641 Felix Biotechnology/ Yale University Priority pathogens Acinetobacter baumannii Critical priority pathogens N/A N/A Yes NA NA WHO AMR pipeline analysis Nov-21 Zidebactam + cefepime – Antibiotics NA DBO-BLI/ PBP2 binder + cephalosporin Gram-negative bacterial infections IV Phase I NCT02532140, NCT02942810, NCT02707107 Wockhardt Ltd. Priority pathogens Streptococcus pneumoniae Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 Zidebactam + cefepime – Antibiotics NA DBO-BLI/ PBP2 binder + cephalosporin Gram-negative bacterial infections IV Phase I NCT02532140, NCT02942810, NCT02707107 Wockhardt Ltd. Priority pathogens Staphylococcus aureus Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 Zidebactam + cefepime – Antibiotics NA DBO-BLI/ PBP2 binder + cephalosporin Gram-negative bacterial infections IV Phase I NCT02532140, NCT02942810, NCT02707107 Wockhardt Ltd. Priority pathogens Pseudomonas aeruginosa Critical priority pathogens Yes No Yes NA NA WHO AMR pipeline analysis Nov-21 Zidebactam + cefepime – Antibiotics NA DBO-BLI/ PBP2 binder + cephalosporin Gram-negative bacterial infections IV Phase I NCT02532140, NCT02942810, NCT02707107 Wockhardt Ltd. Priority pathogens Other priority pathogens Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 Zidebactam + cefepime – Antibiotics NA DBO-BLI/ PBP2 binder + cephalosporin Gram-negative bacterial infections IV Phase I NCT02532140, NCT02942810, NCT02707107 Wockhardt Ltd. Priority pathogens Neisseria gonnorhoeae Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 Zidebactam + cefepime – Antibiotics NA DBO-BLI/ PBP2 binder + cephalosporin Gram-negative bacterial infections IV Phase I NCT02532140, NCT02942810, NCT02707107 Wockhardt Ltd. Priority pathogens Helicobacter pylori Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 Zidebactam + cefepime – Antibiotics NA DBO-BLI/ PBP2 binder + cephalosporin Gram-negative bacterial infections IV Phase I NCT02532140, NCT02942810, NCT02707107 Wockhardt Ltd. Priority pathogens Gram-positive priority pathogens Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 Zidebactam + cefepime – Antibiotics NA DBO-BLI/ PBP2 binder + cephalosporin Gram-negative bacterial infections IV Phase I NCT02532140, NCT02942810, NCT02707107 Wockhardt Ltd. Priority pathogens Enterococcus faecium Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 Zidebactam + cefepime – Antibiotics NA DBO-BLI/ PBP2 binder + cephalosporin Gram-negative bacterial infections IV Phase I NCT02532140, NCT02942810, NCT02707107 Wockhardt Ltd. Priority pathogens Enterobacterales Critical priority pathogens Yes No Yes NA NA WHO AMR pipeline analysis Nov-21 Zidebactam + cefepime – Antibiotics NA DBO-BLI/ PBP2 binder + cephalosporin Gram-negative bacterial infections IV Phase I NCT02532140, NCT02942810, NCT02707107 Wockhardt Ltd. Priority pathogens Critical priority pathogens Critical priority pathogens Yes No Yes NA NA WHO AMR pipeline analysis Nov-21 Zidebactam + cefepime – Antibiotics NA DBO-BLI/ PBP2 binder + cephalosporin Gram-negative bacterial infections IV Phase I NCT02532140, NCT02942810, NCT02707107 Wockhardt Ltd. Priority pathogens Campylobacter spp. Other priority pathogens N/A No Yes NA NA WHO AMR pipeline analysis Nov-21 Zidebactam + cefepime – Antibiotics NA DBO-BLI/ PBP2 binder + cephalosporin Gram-negative bacterial infections IV Phase I NCT02532140, NCT02942810, NCT02707107 Wockhardt Ltd. Priority pathogens All critical priority pathogens Critical priority pathogens Yes No Yes NA NA WHO AMR pipeline analysis Nov-21 Zidebactam + cefepime – Antibiotics NA DBO-BLI/ PBP2 binder + cephalosporin Gram-negative bacterial infections IV Phase I NCT02532140, NCT02942810, NCT02707107 Wockhardt Ltd. Priority pathogens Acinetobacter baumannii Critical priority pathogens Yes No Yes NA NA WHO AMR pipeline analysis Nov-21 Zoliflodacin – Antibiotics NA Topoisomerase Inhibitors (Spiropyrimidenetrione) Uncomplicated N. gonorrhoeae Oral Phase III NCT03959527 Entasis Therapeutics Inc./ GARDP Priority pathogens Streptococcus pneumoniae Other priority pathogens No Yes Yes NA NA WHO AMR pipeline analysis Nov-21 Zoliflodacin – Antibiotics NA Topoisomerase Inhibitors (Spiropyrimidenetrione) Uncomplicated N. gonorrhoeae Oral Phase III NCT03959527 Entasis Therapeutics Inc./ GARDP Priority pathogens Staphylococcus aureus Other priority pathogens No Yes Yes NA NA WHO AMR pipeline analysis Nov-21 Zoliflodacin – Antibiotics NA Topoisomerase Inhibitors (Spiropyrimidenetrione) Uncomplicated N. gonorrhoeae Oral Phase III NCT03959527 Entasis Therapeutics Inc./ GARDP Priority pathogens Pseudomonas aeruginosa Critical priority pathogens No Yes Yes NA NA WHO AMR pipeline analysis Nov-21 Zoliflodacin – Antibiotics NA Topoisomerase Inhibitors (Spiropyrimidenetrione) Uncomplicated N. gonorrhoeae Oral Phase III NCT03959527 Entasis Therapeutics Inc./ GARDP Priority pathogens Other priority pathogens Other priority pathogens Yes Yes Yes NA NA WHO AMR pipeline analysis Nov-21 Zoliflodacin – Antibiotics NA Topoisomerase Inhibitors (Spiropyrimidenetrione) Uncomplicated N. gonorrhoeae Oral Phase III NCT03959527 Entasis Therapeutics Inc./ GARDP Priority pathogens Neisseria gonnorhoeae Other priority pathogens Yes Yes Yes NA NA WHO AMR pipeline analysis Nov-21 Zoliflodacin – Antibiotics NA Topoisomerase Inhibitors (Spiropyrimidenetrione) Uncomplicated N. gonorrhoeae Oral Phase III NCT03959527 Entasis Therapeutics Inc./ GARDP Priority pathogens Helicobacter pylori Other priority pathogens No Yes Yes NA NA WHO AMR pipeline analysis Nov-21 Zoliflodacin – Antibiotics NA Topoisomerase Inhibitors (Spiropyrimidenetrione) Uncomplicated N. gonorrhoeae Oral Phase III NCT03959527 Entasis Therapeutics Inc./ GARDP Priority pathogens Gram-positive priority pathogens Other priority pathogens No Yes Yes NA NA WHO AMR pipeline analysis Nov-21 Zoliflodacin – Antibiotics NA Topoisomerase Inhibitors (Spiropyrimidenetrione) Uncomplicated N. gonorrhoeae Oral Phase III NCT03959527 Entasis Therapeutics Inc./ GARDP Priority pathogens Enterococcus faecium Other priority pathogens No Yes Yes NA NA WHO AMR pipeline analysis Nov-21 Zoliflodacin – Antibiotics NA Topoisomerase Inhibitors (Spiropyrimidenetrione) Uncomplicated N. gonorrhoeae Oral Phase III NCT03959527 Entasis Therapeutics Inc./ GARDP Priority pathogens Enterobacterales Critical priority pathogens No Yes Yes NA NA WHO AMR pipeline analysis Nov-21 Zoliflodacin – Antibiotics NA Topoisomerase Inhibitors (Spiropyrimidenetrione) Uncomplicated N. gonorrhoeae Oral Phase III NCT03959527 Entasis Therapeutics Inc./ GARDP Priority pathogens Critical priority pathogens Critical priority pathogens No Yes Yes NA NA WHO AMR pipeline analysis Nov-21 Zoliflodacin – Antibiotics NA Topoisomerase Inhibitors (Spiropyrimidenetrione) Uncomplicated N. gonorrhoeae Oral Phase III NCT03959527 Entasis Therapeutics Inc./ GARDP Priority pathogens Campylobacter spp. Other priority pathogens No Yes Yes NA NA WHO AMR pipeline analysis Nov-21 Zoliflodacin – Antibiotics NA Topoisomerase Inhibitors (Spiropyrimidenetrione) Uncomplicated N. gonorrhoeae Oral Phase III NCT03959527 Entasis Therapeutics Inc./ GARDP Priority pathogens All critical priority pathogens Critical priority pathogens No Yes Yes NA NA WHO AMR pipeline analysis Nov-21 Zoliflodacin – Antibiotics NA Topoisomerase Inhibitors (Spiropyrimidenetrione) Uncomplicated N. gonorrhoeae Oral Phase III NCT03959527 Entasis Therapeutics Inc./ GARDP Priority pathogens Acinetobacter baumannii Critical priority pathogens No Yes Yes NA NA WHO AMR pipeline analysis Nov-21 GSK3036656 GSK070 Antibiotics NA Leu RS inhibitor (oxaborole) Pulmonary tuberculosis Oral Phase II NCT03557281 GlaxoSmithKline PLC Mycobacterium tuberculosis Mycobacterium tuberculosis N/A N/A Yes Yes y NA WHO AMR pipeline analysis Nov-21 BTZ-043 - Antibiotics NA DprE1 inhibitor (benzothiazinone) Tuberculosis Oral Phase II NCT03590600, NCT04044001 University of Munich; Hans Knöll Institute, Jena; German Center for Infection Research Mycobacterium tuberculosis Mycobacterium tuberculosis N/A N/A Yes Yes y NA WHO AMR pipeline analysis Nov-21 BVL-GSK098 - Non-traditional Miscellaneous Amido piperidine (inactivation of TetR-like repressor, EthR2) Tuberculosis Oral Phase I NCT04654143 Bioversys/ GSK Mycobacterium tuberculosis Mycobacterium tuberculosis N/A N/A N/A Yes y NA WHO AMR pipeline analysis Nov-21 Delpazolid LCB01-0371 Antibiotics NA Oxazolidinone Pulmonary tuberculosis, Gram-positive bacterial infections Oral Phase II NCT02836483, NCT04550832 LegoChem Biosciences Inc., HaiHe Biopharma Mycobacterium tuberculosis Mycobacterium tuberculosis N/A N/A No Yes y NA WHO AMR pipeline analysis Nov-21 GSK2556286 GSK286 Antibiotics NA Undisclosed Tuberculosis Oral Phase I NCT04472897 GSK. TB Drug Accelarator/ Bill & Melinda Gates Foundation Mycobacterium tuberculosis Mycobacterium tuberculosis N/A N/A Yes Yes y NA WHO AMR pipeline analysis Nov-21 Macozinone PBTZ-169 Antibiotics NA DprE1 inhibitor (Benzothiazinone) Pulmonary tuberculosis Oral Phase I NCT03036163, NCT03776500, NCT03334734 Innovative Medicines for Tuberculosis Foundation and Nearmedic Plus Mycobacterium tuberculosis Mycobacterium tuberculosis N/A N/A Yes Yes y NA WHO AMR pipeline analysis Nov-21 OPC-167832 – Antibiotics NA DprE1 inhibitor (3,4-dihydrocarbostyril) Pulmonary tuberculosis Oral Phase II NCT03678688 Otsuka Pharmaceutical Co., Ltd. Mycobacterium tuberculosis Mycobacterium tuberculosis N/A N/A Yes Yes y NA WHO AMR pipeline analysis Nov-21 Sutezolid PNU-100480 Antibiotics NA Oxazolidinone Pulmonary tuberculosis, Gram-positive bacterial infections Oral Phase II NCT03959566 TB Alliance/ Sequella Mycobacterium tuberculosis Mycobacterium tuberculosis N/A N/A No Yes y NA WHO AMR pipeline analysis Nov-21 TBA-7371 – Antibiotics NA DprE1 inhibitor (azaindole) Tuberculosis Oral Phase II NCT04176250, NCT03199339 TB Alliance/ Bill & Melinda Gates Medical Research Institute/ Foundation for Neglected Disease Research Mycobacterium tuberculosis Mycobacterium tuberculosis N/A N/A Yes Yes y NA WHO AMR pipeline analysis Nov-21 TBAJ-587 - Antibiotics NA Diarylquinoline Tuberculosis Oral Phase I NCT04890535 TB Alliance Mycobacterium tuberculosis Mycobacterium tuberculosis N/A N/A No Yes y NA WHO AMR pipeline analysis Nov-21 TBAJ-876 - Antibiotics NA Diarylquinoline Tuberculosis Oral Phase I NCT04493671 TB Alliance Mycobacterium tuberculosis Mycobacterium tuberculosis N/A N/A No Yes y NA WHO AMR pipeline analysis Nov-21 TBI-166 pyrifazimine Antibiotics NA Riminophenazine (clofazimine-analogue) Tuberculosis Oral Phase I NCT04670120 Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College Mycobacterium tuberculosis Mycobacterium tuberculosis N/A N/A No Yes y NA WHO AMR pipeline analysis Nov-21 TBI-223 - Antibiotics NA Oxazolidinone Tuberculosis Oral Phase I NCT03758612, NCT04865536 Institute of Materia Medica/ TB Alliance Mycobacterium tuberculosis Mycobacterium tuberculosis N/A N/A No Yes y NA WHO AMR pipeline analysis Nov-21 Telacebec Q203 Antibiotics NA Imidazopyridine amide Pulmonary tuberculosis Oral Phase II NCT03563599, NCT04847583 Qurient Co Mycobacterium tuberculosis Mycobacterium tuberculosis N/A N/A Yes Yes y NA WHO AMR pipeline analysis Nov-21 ART24 - Non-traditional Microbiome-modulating agents Live biotherapeutic product C. difficile infections Oral Phase I NCT04891965 Artugen Therapeutics Clostridioides difficile Clostridioides difficile N/A N/A N/A Yes NA y WHO AMR pipeline analysis Nov-21 BB128 - Non-traditional Microbiome-modulating agents Live biotherapeutic product Recurring C. difficile infections Colonoscopy Preregistration - BiomeBank Clostridioides difficile Clostridioides difficile N/A N/A N/A Yes NA y WHO AMR pipeline analysis Nov-21 CP101 – Non-traditional Microbiome-modulating agents Live biotherapeutic product Recurring C. difficile infections Oral Phase II NCT03110133, NCT03497806 Finch Theraputics Clostridioides difficile Clostridioides difficile N/A N/A N/A Yes NA y WHO AMR pipeline analysis Nov-21 CRS3123 REP 3123 Antibiotics NA Diaryldiamine (Methionyl-tRNA synthetase inhibitor) C. difficile infections Oral Phase II NCT04781387 Crestone/ National Institute of Allergy and Infectious Diseases Clostridioides difficile Clostridioides difficile N/A N/A Yes Yes NA y WHO AMR pipeline analysis Nov-21 DAV132 – Non-traditional Microbiome-modulating agents Antibiotic inactivator and protective colon-targeted adsorbent C. difficile infections Oral Phase II NCT03710694 Da Volterra Clostridioides difficile Clostridioides difficile N/A N/A N/A Yes NA y WHO AMR pipeline analysis Nov-21 DNV3837 MCB-3837 Antibiotics NA Oxazolidinone-quinolone hybrid C. difficile infections IV Phase II NCT03988855 Deinove Clostridioides difficile Clostridioides difficile N/A N/A Inconclusive Yes NA y WHO AMR pipeline analysis Nov-21 Ibezapolstat ACX-362E Antibiotics NA Substituted guanine (DNA polymerae IIIIC inhibitor)) C. difficile infections Oral, Not absorbed Phase II NCT04247542 Acurx Pharmaceuticals Clostridioides difficile Clostridioides difficile N/A N/A Yes Yes NA y WHO AMR pipeline analysis Nov-21 IM-01 – Non-traditional Antibodies anti-C. difficile polcyclonal Ab C. difficile infections Oral Phase II NCT04121169 ImmuniMed Clostridioides difficile Clostridioides difficile N/A N/A N/A Yes NA y WHO AMR pipeline analysis Nov-21 LMN-201 - Non-traditional Bacteriophages and phage-derived enzymes Phage endolysin and three toxin-binding proteins (5D, E3, and 7F)s C. difficile infections Oral Phase I NCT04893239 Lumen Bioscience Clostridioides difficile Clostridioides difficile N/A N/A N/A Yes NA y WHO AMR pipeline analysis Nov-21 MET-2 - Non-traditional Microbiome-modulating agents Live biotherapeutic product Recurring C. difficile infections Oral Phase I NCT02865616, NCT04602715 NuBiyota/ Takeda Clostridioides difficile Clostridioides difficile N/A N/A N/A Yes NA y WHO AMR pipeline analysis Nov-21 MGB-BP-3 – Antibiotics NA DNA minor groove binder (distamycin) C. difficile-associated diarrhea Oral, Not absorbed Phase II NCT03824795 MGB Biopharma Ltd. Clostridioides difficile Clostridioides difficile N/A N/A Yes Yes NA y WHO AMR pipeline analysis Nov-21 RBX2660 Non-traditional Microbiome-modulating agents Live biotherapeutic product C. difficile Enema Phase III NCT03931941 Ferring Pharmaceuticals Clostridioides difficile Clostridioides difficile N/A N/A N/A Yes NA y WHO AMR pipeline analysis Nov-21 RBX7455 - Non-traditional Microbiome-modulating agents Live biotherapeutic product Recurring C. difficile infections Oral Phase I NCT02981316 Ferring (Rebiotix) Clostridioides difficile Clostridioides difficile N/A N/A N/A Yes NA y WHO AMR pipeline analysis Nov-21 Ridinilazole SMT19969 Antibiotics NA Bis-benzimidazole C. difficile infections Oral, Not absorbed Phase III NCT02784002, NCT02092935, NCT03595553, NCT03595566, NCT04802837 Summit Therapeutics Inc. Clostridioides difficile Clostridioides difficile N/A N/A Yes Yes NA y WHO AMR pipeline analysis Nov-21 SER-109 - Non-traditional Microbiome-modulating agents Live biotherapeutic product C. difficile infections Oral Phase III NCT03183128, NCT03183141 Seres Theraputics Clostridioides difficile Clostridioides difficile N/A N/A N/A Yes NA y WHO AMR pipeline analysis Nov-21 SYN-004 Ribaxamase Non-traditional Microbiome-modulating agents Antibiotic inactivator C. difficile infections Oral Phase II NCT02563106, NCT04692181 Synthetic Biologics Clostridioides difficile Clostridioides difficile N/A N/A N/A Yes NA y WHO AMR pipeline analysis Nov-21 VE303 – Non-traditional Microbiome-modulating agents Live biotherapeutic product Recurring C. difficile infections Oral Phase II NCT03788434 Vedanta Biosciences Clostridioides difficile Clostridioides difficile N/A N/A N/A Yes NA y